RATE CONTRACT

FOR PROCUREMENT OF REAGENTS KITS AND IMMUNOHISTOCHEMISTRY ANTIBODIES

All India Institute of Medical Sciences, Jodhpur

NIT No. : PROC-2/RC/04/2024-AIIMS.JDH

NIT Issue Date : 11th October, 2024

Last Date of Submission : 13th November, 2024 at 1500 HRS

Date of Opening : 14th November, 2024 at 1100 HRS

Pre-Bid Meeting : 23rd October, 2024 at 1500 HRS

Tender documents may be downloaded from institute's web site www.aiimsjodhpur.edu.in (for reference only) and CPPP site https://eprocure.gov.in/eprocure/app



All India Institute of Medical Sciences, Jodhpur

Basni Phase – II, Jodhpur – 342 005, Rajasthan

Phone: 0291-2740741, Email: procurement.aiimsjodhpur@gmail.com

Website: http://www.aiimsjodhpur.edu.in

All India Institute of Medical Sciences (AIIMS), Jodhpur (Rajasthan) an apex healthcare institute established by an Act of Parliament of India under aegis of Ministry of Health & Family Welfare, Government of India, invites Online Bids in Two Bid System for Rate Contract for procurement of Reagents kits and immunohistochemistry antibodies at AIIMS Jodhpur. You are requested to quote your best offer along with the complete details of specifications, terms & conditions as mentioned in the succeeding paragraphs.

General Instructions to Bidders:

- 1. Bids shall be submitted online only at CPP Portal website: https://eprocure.gov.in.
- 2. The complete bidding process is **ONLINE**. The Bidder should be in possession of valid Digital Signature Certificate (DSC) for online submission of bids. Prior to the bidding, DSC needs to be registered on the mentioned above website. For any assistance for e-Bidding Process, if required, bidder may contact to the Help Desk at 0291-2740741.
- 3. Tenderers / Bidders are advised to follow the instructions provided in the 'General Instructions to the Bidders' for the e-submission of the bids online through the Central Public Procurement Portal at https://eprocure.gov.in.
- 4. Bid documents as mentioned in the succeeding paragraphs to be scanned with 100 dpi with black and white option which helps in reducing size of the scanned document.
- 5. Bid Security (Earnest Money): The bidder shall be required to submit the Bid Security (Earnest Money) for an amount of ₹ 1,00,000 /- by way of Demand Draft / FDR / Bank Guarantee [ANNEXURE-VIII] only. The Bid Security (Earnest Money) shall be drawn in favour of "All India Institute of Medical Sciences, Jodhpur".
 - a) The Bid Security (Earnest Money) of the Unsuccessful Bidders shall be returned after the *Award of Contract*.
 - b) The Bid Security (Earnest Money) of Successful Bidders shall be returned after the receipt of Performance Security.
 - c) No request for transfer of any pervious Bid Security or Performance Security or Payment of any Pending Bill held by the institute, in respect of any previous work, will be entertained.
 - d) The bidder is not permitted to withdraw his offer or modify the terms and conditions thereof. In case the bidder fails to observe and comply with the conditions made herein or backs out after quoting the rates, the Earnest Money will be forfeited.
 - e) The Bid Security (Earnest Money) has to be submitted by all the bidders except Micro and Small Enterprises (MSEs) as defined in MSE Procurement Policy issued by Department of Micro, Small and Medium Enterprises (MSME) or are registered with the Central Purchase Organization or the concerned Ministry or Department [or Startups as recognized by Department for Promotion of Industry and Internal Trade (DPIIT)]. Copy of registration must be provide along with technical bid. No other relaxation shall be allowed.
 - f) No Claim shall lie against AIIMS- Jodhpur in respect of interest on the amount of Bid Security (Earnest Money).

The Original Hard Copy of only of the Bid Security (Earnest Money) document must be delivered in the office of Deputy Director (Admin), AIIMS, Jodhpur before the last date / time of Bid Submission. The bid without Bid Security (Earnest Money) will be summarily rejected. The copy of Bid Security (Earnest Money) must be attached while submitting / uploading the Technical Bid.

- 6. The bidder must read and examine all the terms, conditions, instructions etc. contained in the NIT. Failure to provide and/or comply with the required information, instructions etc. incorporated in the Tender Documents will result in rejection of Bid.
- 7. The rates quoted, approved and accepted by the Executive Director, AIIMS shall be valid for **Two Years** from the date of **Award of Contract**. (Extendable on mutual agreement, under the same Terms
 & Conditions as prescribed in this contact, if required).

8. SUBMISSION OF TENDER

- a) The bid shall be submitted online in Two Parts viz. (A) TECHNICAL BID and (B) FINANCIAL BID (in the attached BoQ / Excel Sheet at CPP Portal).
- b) All the pages of bid being submitted must be signed and sequentially numbered by the bidder, irrespective of nature of content of the documents before uploading.
- c) The Technical Bid Documents **MUST BE** submitted and sequenced / arranged in the following order, **failing this may result in rejection of the bid** (**MOST IMPORTANT**):

| SEQUENCING | DOCUMENTS |
|------------|---|
| First | Details of the Bidder and Key Person for any communication regarding Rate Contract [Name, Designation, Type of Firm (Sole Proprietor, Partnership, Company, PSU etc.), Contact Number, eMail Address and Office Address]. |
| Second | All the Annexures are to be submitted in proper sequence / order from ANNEXURE-I to ANNEXURE-XI (Except for ANNEXURE-VIII & ANNEXURE-IX). |
| Third | Bid Security (Earnest Money) in the form of Demand Draft or FDR or Bank Guarantee [ANNEXURE-VIII]. |
| Forth | List of Quoted Items [ANNEXURE-IX]. |
| Fifth | Registration Certificate of the firm. |
| Sixth | GST Registration Certificate of the firm. |
| Seventh | PAN Card of the firm. |
| Eighth | No Case Pending Declaration (Must be submitted as affidavit on ₹ 100/- Non-Judicial Stamp Paper). |
| Ninth | Mandate Form / Bank Details. |
| Tenth | Licenses / Certificates as per US-FDA / European CE / Equivalent Indian Standards (wherever applicable). |
| Eleventh | Drug Licenses issued by Central / State Drug Controller. |
| Twelfth | Any other relevant document regarding special instructions / use / storage / shelf life. |
| Thirteenth | Import License issued to the Authorized Agent / Importer by the Government of India. |

| _ | |
|--------------|---|
| Fourteenth | Income Tax Return Acknowledgement for Last Three Assessment Years |
| Fourteentii | (A.Y. 2021-22, 2022-23 & 2023-24). |
| Fifteenth | Average Annual Turnover Certificate / Statement duly verified and audited by Charted |
| riiteeiitii | Accountant (for the F.Y. 2020-21, 2021-22 & 2022-23). |
| Sixteenth | Profit & Loss A/c and Balance Sheet |
| Sixteenth | (in chronological order for F.Y. 2020-21, 2021-22 & 2022-23). |
| Seventeenth | This NIT Document and its Corrigendum (if issued by the institute), all pages duly signed and |
| Seventeentii | stamped. |
| | |
| Eighteenth | Any other relevant document (left to be included in this list). |
| | |

The offer submitted via Telegram / Fax / Email shall not be considered. No correspondence will be entertained in this matter.

GENERAL TERMS AND CONDITIONS

Sub.: Notice Inviting bids for "Rate Contact for procurement of Reagents kits and immunohistochemistry antibodies at AIIMS Jodhpur" at All India Institute of Medical Sciences-Jodhpur.

1. PARTIES

The parties to the contract are the contractor (the bidder to whom the Award of Contract have been awarded) and the AIIMS- Jodhpur through Administrative Officer, All India Institute of Medical Sciences, Jodhpur for and on behalf of the Executive Director, AIIMS, Jodhpur.

2. PRE-BID MEETING

- a) Pre-Bid meeting is scheduled on 23rd October, 2024 at 03:00 PM at Conference Hall, Medical Superintendent Office, OPD Building AIIMS Jodhpur. The bidders are advised to submit representation only through email at procurement.aiimsjodhpur@gmail.com; on or before 22nd October, 2024 till 05:00 PM as well as in Physical Copy during the PRE-BID Meeting only.
- b) The bidder MUST keep the subject of the eMail as "Rate Contact for procurement of Reagents kits and immunohistochemistry antibodies at AIIMS Jodhpur:PROC-2/RC/04/2024-AIIMS.JDH".
- c) The representations received thereafter and on any other Email ID of the Institute will not be entertained.
- 3. The proposal for rate contract may be submitted in the prescribed format and all columns may be filled up. Incomplete proposals and tenders received after due date shall not be entertained. Any bids received by the Institute, which does not fulfill the terms and conditions shall be rejected out rightly and no communication in this regard shall be sent. Delayed / Late Bids will not be accepted, in any circumstance.
- **4.** Bids comprising of such vague and indefinite expression such as *'Subject to prior confirmation'*, *'Subject to immediate acceptance'* etc. will be treated as vague offers and rejected accordingly. Any conditional tender shall be rejected summarily.

- 5. The bidder shall not be permitted to withdraw his offer or modify the terms and conditions thereof. In case the tenderer fails to observe and comply with stipulation made herein or backs out after quoting the rates, the amount of Bid Security (Earnest Money) will be forfeited.
- **6.** At any time prior to date of submission of tender, AIIMS-Jodhpur may, for any reason or decision, modify the terms & conditions of the tender document by a corrigendum displayed on the website of AIIMS-Jodhpur (http://www.aiimsjodhpur.edu.in). In order to provide reasonable time to take the amendment into account in preparing the bid, AIIMS-Jodhpur may, at its discretion, extend the date and time for submission of bids.

7. DOCUMENTS COMPRISING THE BID: The Two Bid System i.e. (A) TECHNICAL BID and (B) FINANCIAL BID

(A) TECHNICAL BID

To qualify in the Technical Bid the firm must fulfill the minimum eligibility criteria as under and the firm in this regard must submit / attach the following documents in support of their eligibility criteria:

- a) Details of the Bidder and Key Person for any communication regarding Rate Contract [Name, Designation, Type of Firm (Sole Proprietor, Partnership, Company, PSU etc.), Contact Number, eMail Address and Office Address] must be submitted.
- b) Technical Information and Undertaking as per Contract Form [ANNEXURE-I].
- c) Manufacturer's Authorization Certificate [ANNEXURE-II], if the bidder is quoting on behalf of the Foreign Company.
- d) Tender Acceptance Form [ANNEXURE-III].
- e) **Non-Blacklisting Certificate** [**ANNEXURE-IV**], that the firm has not been blacklisted in the past by any Government / Private Institution on ₹ 100/- Non-Judicial Stamp Paper.
- f) No Deviation Certificate [ANNEXURE-V] on ₹ 100/- Non-Judicial Stamp Paper.
- g) Price Justification Certificate [ANNEXURE-VI] on ₹ 100/- Non-Judicial Stamp Paper.
- h) The bidder must submit duly filled & signed certificate of Land Border Declaration [ANNEXURE-VII], on ₹ 100/- Non-Judicial Stamp Paper, in compliance of the terms and conditions mentioned in Department of expenditure OM No. 6/18/2019-PPD dated: 23rd July, 2020 and subsequent guidelines issued thereafter.
- i) Copy of **Bid Security (Earnest Money)** in the form of Demand Draft or FDR or Bank Guarantee [**ANNEXURE-VIII**].
- j) List of Quoted Items [ANNEXURE-IX].
- k) Calculation of Local Content [ANNEXURE-X] (if applicable).
- I) Affidavit of Self Certification regarding Local Content [ANNEXURE-XI] on ₹ 100/- Non-Judicial Stamp Paper (if applicable).
- m) Copy of **Valid Registration Certificate** of the firm issued by the Central Government / State Government.
- n) Copy of **GST Registration Certificate** and **PAN Card**.
- o) **No Case Pending Declaration** (Must be submitted as affidavit on ₹ 100/- Non-Judicial Stamp Paper).

- p) Copy of Mandate Form / Bank Details.
- q) Copy of **Licenses / Certificates** as per US-FDA / European CE / Equivalent Indian Standards (wherever applicable).
- r) **Drug Licenses** issued by Central / State Drug Controller if applicable.
- s) Any other relevant document regarding special instructions / use / storage / shelf life.
- t) Copy of Import License issued to the Authorized Agent / Importer by the Government of India.
- u) Copy of **Income Tax Return Acknowledgement** for Last Three Assessment Years (A.Y. 2021-22, 2022-23 & 2023-24).
- v) Copy of **Average Annual Turnover Certificate / Statement** duly verified and audited by Charted Accountant (for the F.Y. 2020-21, 2021-22 & 2022-23) must be attached in the Technical Bid Document. The **Average Annual Turnover** of the bidder from similar jobs should be at least ₹ **02 crore** in the Last Three Financial Years (F.Y. 2020-21, 2021-22 & 2022-23) from the Indian Business.
- w) Copy of **Profit & Loss A/c and Balance Sheet** (in chronological order for F.Y. 2020-21, 2021-22 & 2022-23) also be submitted.
- x) The concerned firm / company whose product has been declared as of spurious or adulterated quality and any criminal cases is filled and is pending in any court shall not be eligible to participate in the bidding process. Convicted firms/company shall also not be eligible to participate in the bid. Similarly, blacklisted / banned / debarred firms / company by any central / state govt. or its organization or autonomous bodies or central drug procurement agency is not eligible to participate in the bid.

(B) FINANCIAL BID

Financial Bid as per BoQ format filled up with all the details including Make (Company) etc. of the goods offered to be uploaded.

Schedule of price bid in the form of BOQ_XXXX.xls:

Price bid format is provided as BoQ_XXXX.xls along with this Tender Enquiry Document at https://eprocure.gov.in/eprocure/app. Bidders are advised to download this BoQ_XXXX.xls as it is and quote their offer/rates in the permitted column and upload the same in the Financial Bid. Bidder shall not tamper/modify the downloaded price bid template in any manner. In case if the same is found to be tampered / modified in any manner, tender will be completely rejected out rightly.

- 8. The Item Names and Specifications are mentioned in List of Items [ANNEXURE-XIV].
- **9.** Full description & specifications, Make (Company) / Brand / Name of the manufacturing firm must be clearly mentioned in the tender failing which the tender will not be considered. The tendered must also mention whether the goods are imported / indigenous. Descriptive literature / catalogues must be attached with the tender in original failing which tender may be ignored.

10. Additional terms and Conditions:

- (a) The IHCs supplied for the first time have to be validated by the vendors in -house.
- (b) RTU antibodies are preferred over concentrated antibodies (unless specified).
- (c) Quantity required is not manufacturer specific. Hence, the vial quantity may be 6 ml vial/7ml vial or 10ml.

11 SIGNING OF TENDER

Individual signing the tender or other documents connected with contract must specify whether he sign as:

- a) A sole proprietor of the concern or constituted attorney of such sole proprietor;
- b) A partner of the firm, if it is a partnership firm in which case he must have authority to execute the contracts on behalf of the firm and to refer to arbitration disputes concerning the business of the partnership either by virtue of the partnership agreement or by a power of attorney duly executed by the partners of the firm.
- c) Director or a principal officer duly authorized by the Board of Directors of the Company, if it is a company.
- d) A person signing the tender form or any document forming part of the tender on behalf of another person should have an authority to bind such other person and if, on enquiry it appears that the person so signing had no authority to do so, AIIMS, Jodhpur may without prejudice, cancel the contract and hold the signatory liable for all costs, consequences and damages under the civil and criminal remedies available.

12 EXCLUSION

The near relatives of employees of AIIMS, Jodhpur are prohibited from participation in this tender. The near relative for this purpose are defined as:

- a) Members of a Hindu Undivided Family.
- b) Their spouses
- c) The one related to the other in the manner as father, son(s), Son's wife (daughter-in-law), daughter(s) and daughter's husband (sons-in-law) brother (s) and brother's wife, sister(s) and sister's husband, brother(s)-in-law.

13 DOCUMENTS

- a) All pages of the Tender should be numbered and indexed.
- b) The bidder shall provide in its tender the required as well as the relevant documents like technical data, literature, drawings etc. to establish that the goods and services offered in the tender fully confirm to the goods and services specified by the AIIMS, Jodhpur in the tender documents. For this purpose, the bidder shall also provide a clause-by-clause commentary on the technical specifications and other technical details incorporated by the AIIMS, Jodhpur in the tender documents to establish technical responsiveness of the goods and services offered in its tender duly indicating relevant page numbers in the product literature.

14 BID CURRENCIES

The bidder supplying indigenous goods or imported goods shall quote only in Indian Rupees (INR). Bids, where prices are quoted in any other currencies shall be treated as non-responsive and will be rejected.

15 BID PRICES

a) The Bidder shall indicate in the Price Schedule provided in BoQ all the specified components of prices shown therein including the unit prices on Free Delivery at Site basis, applicable GST, HSN Code, it proposes to supply against the requirement. The Bidders shall indicate MRP in the relevant column against each item of

BoQ. The details about make & model, if applicable, may also be indicated. All the columns shown in the Price Schedule should be filled up as required.

b) In no case the quoted rates should be more than MRP at the time of submission of quotation. If subsequently during the currency of Rate Contract there is decreased in MRP, the bidder shall inform the purchaser promptly alongwith revised reduced rates. In case, if bidder quotes more than MRP and/or does not inform purchaser about reduction in MRP, it will be viewed seriously and appropriate administrative action will be taken including de-barring the firm.

16 VALIDITY OF THE BIDS

The bids shall be valid for a period of 12 Months from the date of opening of the NIT. In case, the Contract is not finalized within stipulated period, its validity shall be updated via corrigendum(s) on the institute's website.

17 RIGHT OF ACCEPTANCE

- a) The AIIMS, Jodhpur reserve the right to accept the whole or any part or portion of the bid; and the bidder shall provide the same at the rates quoted. The AIIMS Jodhpur reserve the right to reject any or all tenders / quotations or all offers received in response to the tender or cancel or withdraw the tender notice without assigning any reason thereof and also does not bind itself to accept the lowest quotation or any tender and no claim in this regard shall be entertained.
- b) The AIIMS- Jodhpur does not bind itself to accept the lowest bid or any bid and reserves the right of accepting the whole or any part of the bid or portion of the job offered; and the bidder shall provide the same at the rates quoted. AIIMS- Jodhpur, reserves the right to reject any or all offers received in response to tender or cancel or withdraw the tender notice without assigning any reason, whatsoever.
- c) The AIIMS- Jodhpur reserves the right to place an order for purchase of any items mentioned in the Financial Bid or otherwise, to any other firm(s) in emergency/unavoidable situation.
- d) AIIMS- Jodhpur reserves the right to conclude more than one rate contract for the same item.

18 FIRM PRICE

Prices quoted by the bidder shall remain firm and fixed during the period of the Rate Contract and not subject to variation on any account. Purchase Orders will be placed by Centers / Hospital / Departments / Store Sections against this Rate Contract till the period of Rate Contract. Statuary variation in GST will be applicable.

19 ALTERNATIVE MODELS / BRANDS / QUALITY

Alternative Models / Brands / Quality are not permitted. The Bidder are required to quote Models / Brands / Quality of best quality meeting tender specifications. Wherever, a bidder quotes alternative Models / Brands / Quality, there bid will not be considered for that item.

20 PURCHASE PREFERENCE TO LOCAL SUPPLIERS

In pursuance of Government of India Order No. P-45021/2/2017-B.E.-II dated 16th September 2020 (as amended from time to time) and F.No. Z.28018/67/2017-EPW dated 12th June 2018 purchase preference shall be given to local suppliers in all procurements undertaken in the manner specified hereunder and the procurement shall be made as per terms and conditions contained in the said order.

21 MINIMUM LOCAL CONTENT

The minimum local content shall be maintained as per Government of India Order No. P-45021/2/2017-B.E.-II dated 16th September 2020 (as amended from time to time) and F.No. Z.28018/67/2017-EPW dated 12/06/2018, as amended from time to time.

22 MARGIN OF PURCHASE PREFERENCE

The margin of purchase preference shall be 20%. The Local supplier whose quoted price falls in the margin of purchase preference desirous of claiming benefit of the Order No. P-45021/2/2017-B.E.-II dated 16th September 2020 shall submit an undertaking within 7 days of opening of financial bid, that he would be ready to supply the product at L1 price. In case of non-receipt of the same, he would not be given purchase preference.

23 Affidavit of Self Certification regarding Local Content [*Annexure-XI*] on ₹ 100/- Non-Judicial Stamp Paper, except 100% importers.

24 TECHNICAL EVALUATION

- a) Detailed technical evaluation shall be carried out by Purchase Committee / Tender Evaluation Committee pursuant to conditions in the tender document to determine the substantial responsiveness of each tender. For this clause, the substantially responsive bid is one that conforms to all the eligibility and terms and condition of the tender without any material deviation. The Institute's determination of bid's responsiveness is to be based on the contents of the bid itself without recourse to extrinsic evidence. The Institute shall evaluate the technical bids also to determine whether they are complete, whether required sureties have been furnished, whether the documents have been properly signed and whether the bids are in order.
- b) Financial bids of only those bidders who qualify the technical criteria will be opened provided all other requirements are fulfilled.
- c) AIIMS Jodhpur shall have right to accept or reject any or all bidders without assigning any reasons thereof.

25 SAMPLE/DEMONSTRATION

- a) The bidders may be asked to submit samples of the items (if required) for which they have quoted (without indicating price), with clear marking of Firm's Name in each of item, Tender Reference number and all the expenses for sample/demonstration shall be borne by the bidder.
- b) The samples are required to be submitted at **Central Store**, **AIIMS Jodhpur** in original packing, duly labelled (printed) and sealed having all relevant details such as manufacturing date, expiry date, batch number etc.
- c) The sample received from bidders will be evaluated by the Technical Evaluation Committee for their quality and the decision of the Committee will be final.

26 FINANCIAL EVALUATION

- a) The financial bid shall be opened for only those bidders who are found to be technically eligible through the CPP Portal only.
- b) Arithmetical errors shall be rectified on the following basis. If there is a discrepancy between the unit price and total price that is, the unit price shall prevail and the total price shall be corrected by the Institute. If there is a discrepancy between words and figures, the lesser amount shall be considered as valid. If the Supplier does not accept the correction of the errors, that bid shall be rejected.

27 RIGHT TO CALL UPON INFORMATION

- a) The AIIMS, Jodhpur will have the right to call upon information regarding status of work / job at any point of time.
- b) To assist in the analysis, evaluation and computation of the bids, the Purchase Committee / Tender Evaluation Committee of AIIMS, Jodhpur, may ask bidders individually for clarification of their bids. The request for clarification and the response shall be in writing but no change in the price or substance of the bid offered shall be permitted.
- The Purchase Committee / Technical Evaluation Committee of AIIMS, Jodhpur shall go into all aspects including cost factors of Consumables and then decide for awarding of the tender, by quoting lower rates in respect of items, a firm does not become entitled to awarding the contract in its favor of those item(s). In order to get selection / consideration in the panel of two or three vendors for awarding of contract (in case the contract is to be awarded to more than one vendor), the criteria of selection for awarding contract will be calculating / comparing the rate of items consumed by the AIIMS-Jodhpur throughout the year and as per the requirement in view of quality, as deemed fit by the Purchase Committee / Technical Evaluation Committee.

29 PERFORMANCE SECURITY

- a) The Successful bidder shall be required to submit the Performance Security (in the form of Demand Draft / FDR / irrevocable Bank Guarantee [*ANNEXURE-XII*] duly issued by any Nationalized Bank) for an amount in multiplication of ₹ 10,000/- for each Awarded Item, subject to Minimum of ₹ 2,00,000/- and Maximum of ₹ 5,00,000/-.
- b) Performance Security must be valid at least up to Two Years + Sixty Days from the date of Award of Contract.
- c) The Performance Security of successful bidders will be refunded / released after the completion of all contractual obligations and/or till the validity of the Performance Security, whichever is later. If the contract is extended on mutual agreement, it will be renewed accordingly.
- d) The Performance Security can be forfeited by the Institute in the event of any breach or negligence or non-observance of any condition of contract or for unsatisfactory performance or non-observance of any condition of the contract.
- e) No interest on Performance Security shall be paid by the Institute to the bidder.

30 AWARD OF CONTRACT

- a) The Institute shall consider placement of orders to those bidders whose offers have been found Technically and Financially Acceptable. The Institute reserves the right to counter offer price(s) against price(s) quoted by any bidder. The L-1 Bidder will be decided on individual item basis.
- b) AIIMS Jodhpur has the option to renegotiate the price with the Awardee of Contract.
- c) The Award of Contract shall be issued to the L-1 bidders for **Two Years**, valid from the date of issue of Award of Contract (extendable on mutual agreement).
- d) AIIMS-Jodhpur shall reserve the right to terminate the contract at any time without assigning any reason thereof.

31 AUTHORIZED DISTRIBUTOR

- a) The Original Manufacturer (OM), after receipt of *Award of Contract*, may furnish the details of their Authorized Distributor, so that the copies of orders can be endorsed to them for expeditious supply. In such cases where Indian Agent has been nominated by the manufacturer, the bills raised by them against our purchase order will be accepted.
- b) Any addition and deletion of Authorized Distributorship shall be intimated to AIIMS- Jodhpur, immediately on authorization of a new party.

32 SUBLETTING OF WORK

The Authorized Distributor shall not assign or sublet the work/job or any part of it to any other person or party.

33 The Awardee of Contract shall provide the name and mobile number of a Key Person, who can be contacted at any time, even beyond the office hours on holidays. The person should be capable of taking orders and making arrangement for supply of the desired items even on short notice to AIIMS, Jodhpur.

34 PLACEMENT OF PURCHASE ORDER

- a) The Purchase Orders shall be issued for requirement on actual need basis.
- b) All India Institute of Medical Sciences (AIIMS), Jodhpur shall be the sole authority to cancel or amend the Purchase Order, as per requirement, and also to place Purchase Orders beyond Office Hours / Holidays / Place of Supply, for which no additional payment shall be made.

35 PACKING

- a) Supplies to be made in a Proper Boxes with proper packaging.
- b) Packing should be able to prevent damage or deterioration during transit.
- c) All containers, i.e., bottles, tins, cartons, tubes etc. are required to be secured with pilfer-proof seals to ensure genuineness of the products packed and the correctness of the contents.
- d) Each unit / items must be clearly stamped- "Only Govt. supply Not for sale".

36 DELIVERY

- a) Delivery of Goods shall be made by the supplier within *30 days of placing of Purchase Order*, at the location mentioned in the Purchase Order issued.
- b) We being a Healthcare Institute, time is the essence of every Purchase Order, hence, the supplier firm should have availability of a responsible person on call 24x7 on all days, to accept and deliver the items at a **very short notice i.e. within 24 hours also**. The delivery period will be mentioned in the Purchase Order.
- c) The supply must be made in full against the Purchase Orders and shortage will be procured from other supplier on the risk and cost of the Original Supplier.
- d) If any item is found to be defective, or not of the desired quality, the same shall be replaced immediately, for which no extra payment shall be made by AIIMS, Jodhpur.

37 LIQUIDATED DAMAGES

Supply of material will have to be completed within the delivery period or period mentioned in the purchased order. The liquidated damages charges @ 0.5% per week shall be imposed if supply made after expiry of delivery period subject to maximum 10% of the total value of relevant goods. Quantum of liquidated damages assessed and levied by the purchaser shall be final and not challengeable by the supplier.

38 INSPECTION

- a) AIIMS, Jodhpur shall have the right to inspect and/or to test the goods to confirm their conformity to the NIT Specifications at no extra cost to the AIIMS, Jodhpur.
- b) AIIMS, Jodhpur shall have the right to inspect, test and, where necessary, reject the Goods after the goods arrival at the final destination shall in no way be limited or waived by reason of the Goods having previously been inspected, tested and passed by AIIMS, Jodhpur prior to the goods shipment.
- c) The Executive Director, AIIMS Jodhpur shall be the final authority to reject full or any part of the supply which is not confirming to the specification and other terms and conditions.
- d) No payment shall be made for rejected Stores. Rejected items must be removed by the Bidders within Two Days of the date of rejection at their own cost and replaced immediately. In case these are not removed, these will be auctioned at the risk and responsibility of the suppliers without any further notice.
- e) In case the quality of goods supplied are not in conformity with the standard given in tender and as per the samples supplied or the supplies are found defective at any stage these goods shall immediately will be taken back by the supplier and will be replaced with the tender quality goods, without any delay. The Purchase Committee reserves all right to reject the goods if the same are not found in accordance with the required description / specifications and liquidates damages shall be charged.
- f) Supply should be made from the latest batch of production with at least 75% shelf life & original packing.

39 REPLACEMENT OF EXPIRED ITEM

- a) Expired items will be exchanged within Two Days by the supplier with fresh lot as informed by the Department / Central Store. No communication in this regard will be entertained regarding timely information / prior to expiry of items.
- b) If the supplier fails to exchange the expired goods / items within the timeframe, it will be termed as breach of contract conditions, AIIMS Jodhpur reserves the right to initiate any suitable action against the supplier in this regards.
- c) The supplier shall arrange to effect free replacement of any quantity which may deteriorate in potency, strength approaching expiry or expired etc. before the date of expiry marked on the labels.

40 THE PAYMENT CLAUSE

- a) Payment of the bill will be made after receipt of the goods in satisfactory condition and inspection by the concern Committee.
- b) The GST Invoice in Triplicate must be sent to the Delivery Location along with the supplied goods. The bill should have full particulars of the items(s) viz. Item's complete name, Tender Reference Number, HSN Code, Basic Rate, GST Percentage, GST Amount, Total Amount (in numbers & words).
- c) If the items mentioned in Purchase Order is supplied in Part Supply then the payment will be made only after receipt of Full Supply. No part payment will be made in any case.
- d) Freight, insurance charges, if any will be borne by the supplier, Similarly shortage, pilferage in transit will be sole responsibility of the supplier and the same will be intimated to the supplier on receipt of goods by the purchaser for resupply. The defective supply will have to be replaced by the supplier within Two Days without additional freight / transport charge etc.

- e) GST and other Government Levies shall be paid extra, as applicable.
- f) No payment shall be made in advance nor shall the loan from any bank or financial institutions be recommended on the basis of the order of award of work.
- g) Delivery of goods will be taken at the risk and cost of the supplier and on F.O.R. basis to the Institute from railway / road transport.
- h) No revision in rate (on higher side) will be accepted during contract period.
- i) No payment will be made for goods rejected.

41 RISK & COST PURCHASE

If supplier fails to supply material within the stipulated delivery date or material supplied other than specification specified in our NIT, AIIMS Jodhpur reserves the right to terminate contract for that item(s), forfeiture of security deposit and to procure same or equivalent material from alternative sources at the vendor's risk, responsibility and cost. Any extra cost incurred in the procurement of the material from alternative source will be recovered from the Security Deposit / Bank Guarantee and Pending Bills of existing firm and if the value of the materials under risk purchase exceeds, the amount of Security Deposit and / or Bank Guarantee and Pending Bills, the same may be recovered if necessary.

42 FORCE MAJEURE

If, at any time during the subsistence of this contract, the performance in whole or in part by either party of any obligation under this contract is prevented or delayed by reasons of any war or hostility, act of public enemy, civil commotion, sabotage, fire, floods, explosion, epidemics, quarantine restriction, strikers lockout or act of God provided notice of happening of any such eventuality is given by party to other within 21 days from the date of occurrence thereof, neither party shall by reason of such event be entitled to terminate this contract nor shall either party have any claim for damages against other in respect of such non-performance or delay in performance, and deliveries have been so resumed or not shall be final and conclusive.

43 INSOLVENCY / BANKRUPTCY

In the event of the firm being adjudged insolvent or having a receiver appointed for it by a court or any other order under the Insolvency Act made against them or in the case of a company the passing any resolution or making of any order for winding up, whether voluntary or otherwise, or in the event of the firm failing to comply with any of the conditions herein specified AIIMS, Jodhpur shall have the power to terminate the contract without any prior notice and any other action as per the government guidelines will be taken against the bidder.

44 FALL CLAUSE (wherever applicable as per Government's Guidelines)

If at any time during the period of contract, the price of tendered items is reduced or brought down by any law or act of the Central or State Govt. or by the tenderer himself, the tenderer shall be morally and statutorily bound to inform AIIMS, Jodhpur immediately about such reduction in the contracted prices. The AIIMS, Jodhpur is empowered to unilaterally effect such reduction as is necessary in rates in case the tenderer fails to notify or fails to agree for such reduction of rates. In case of any

enhancement in TAXES due to statutory Act of the Govt. after the date of submission of the tenders and during the tender period, the additional TAXES so levied will be allowed to be charged extra as separate item without any change in price structure of the drugs approved under the tender.

45 ARBITRATION

If any conflict or difference arises concerning this agreement, its interpretation on payment to made there-under, the same shall be settled out by mutual consultation and negotiation. If attempts for conciliation do not yield any result within a period of 30 days, either of the parties may make a request to the other party for submission of the dispute for decision by an Arbitral Tribunal containing Sole Arbitrator to be appointed by the Executive Director, AIIMS Jodhpur. Such requests shall be accompanied with a panel of names of three persons to act as the sole arbitrator. In case of such arbitrator refusing, unwilling or becoming incapable to act or his mandate having been terminated under law, another arbitrator shall be appointed in the same manner from among the panel of three persons to be submitted by the claimant. The provision of Arbitration and Conciliation Act, 1996 and the rule framed there under and in force shall be applicable to such proceedings.

46 LEGAL JURISDICTION

The agreement shall be deemed to have been concluded in Jodhpur, Rajasthan and all obligations hereunder shall be deemed to be located at Jodhpur, Rajasthan and Court within Jodhpur, Rajasthan will have Jurisdiction to the exclusion of other courts.

47 The tendering Firm/Agency/Company shall be bound by the details furnished by him/her to the All India Institute of Medical Sciences (AIIMS), Jodhpur while submitting the tender or at subsequent stage. Upon selection of the tendering Firm/Agency/Company, if at any stage, the documents furnished by him/her is found to be false or the quality of the articles found of poor quality/different specifications, it would be deemed to be a breach of terms of contract and the contract shall be cancelled at the discretion of competent authority and performance security shall be stand forfeited.

Executive Director AIIMS, Jodhpur

ANNEXURE-I [CONTRACT FORM]

TECHNICAL INFORMATION AND UNDERTAKING

The bidders are advised to fill prescribed Proforma & enclosed relevant document as per requirement & sequence of given Proforma. The bidder should mention Page Number with all required details of relevant document in the prescribed Proforma. If the bidder does not fill the prescribed given Proforma their offer shall be *summarily rejected & no correspondence will be entertained*.

| Sr. | Details of the documents to be submitted | Page | Remarks |
|-----|--|------|---------|
| 1 | Details of the Bidder and Key Person for any communication regarding Rate Contract [Name, Designation, Type of Firm (Sole Proprietor, Partnership, Company, PSU etc), Contact Number, eMail Address and Office Address]. | | |
| 2 | Contract Form [ANNEXURE-I] | | |
| 3 | Manufacturer's Authorization Certificate [ANNEXURE-II] | | |
| 4 | Tender Acceptance Form [ANNEXURE-III] | | |
| 5 | Non-Blacklisting Certificate [ANNEXURE-IV] | | |
| 6 | No Deviation Certificate [ANNEXURE-V] | | |
| 7 | Price Justification Certificate [ANNEXURE-VI] | | |
| 8 | Land Border Declaration [ANNEXURE-VII] | | |
| 9 | Bid Security (Earnest Money) in the form of Demand Draft or FDR or Bank Guarantee [ANNEXURE-VIII]. | | |
| 10 | List of Quoted Items [ANNEXURE-IX] | | |
| 11 | Calculation of Local Content [ANNEXURE-X] | | |
| 12 | Affidavit of Self Certification regarding Local Content [ANNEXURE-XI] | | |
| 13 | Registration Certificate of the firm. | | |
| 14 | GST Registration Certificate of the firm. | | |
| 15 | PAN Card of the firm. | | |
| 16 | No Case Pending Declaration (Must be submitted as affidavit on ₹ 100/- Non-Judicial Stamp Paper). | | |
| 17 | Mandate Form / Bank Details. | | |
| 18 | Licenses / Certificates as per US-FDA / European CE / Equivalent Indian Standards (wherever applicable). | | |
| 19 | Drug Licenses issued by the Central / State Drug Controller. | | |
| 20 | Any other relevant document regarding special instructions / use / storage / shelf life. | | |
| 21 | Import License issued to the Authorized Agent / Importer by the Government of India. | | |
| 22 | Income Tax Return Acknowledgement for Last Three Assessment Years (A.Y. 2021-22, 2022-23 & 2023-24). | | |

| 23 | Average Annual Turnover Certificate / Statement duly verified and audited by Charted Accountant (for the F.Y. 2020-21, 2021-22 & 2022-23). | |
|----|--|--|
| 24 | Profit & Loss A/c and Balance Sheet (F.Y. 2020-21). | |
| 25 | Profit & Loss A/c and Balance Sheet (F.Y. 2021-22). | |
| 26 | Profit & Loss A/c and Balance Sheet (F.Y. 2022-23). | |
| 27 | This NIT Document and its Corrigendum (if issued by the institute), <i>all pages duly signed and stamped</i> . | |
| 28 | Any other relevant document (left to be included in this list). | |

- Page Number *Must be marked* on each and every page of Tender Documents, Corrigendum(s) and all
 copies of the documents attached.
- The bidder **MUST Mention** Page number in the above Table, wherever the copy(s) of the document(s) are arrange / kept.
- In case of non-fulfilment of any of the above information / document(s), the bid will be summarily rejected, without giving any notice.

| (Dated Signature | of the | Bidder ' | with | stamp | of firm) |
|------------------|--------|----------|------|-------|----------|
|------------------|--------|----------|------|-------|----------|

Dated: Place:

Undertaking

- 1. That I/we have carefully studied all the terms & conditions of NIT and shall abide by it.
- 2. That I/We undertake that the information given in this tender are true and correct in all respect and I/We hold the responsibility for the same.
- 3. That I/We undertake that sample of items will be kept ready for inspections by the AIIMS, Jodhpur. I/We shall be responsible for the cancellation of tender if samples are not up to mark.

(Dated Signature of the Bidder with stamp of firm)

Date: Place:

ANNEXURE-II

[MANUFACTURER'S AUTHORIZATION CERTIFICATE]

| Го | Dated: | |
|---|---------------------------------------|--------------------|
| The Executive Director, | | |
| All India Institute of Medical Sciences, Jodhpur | | |
| MIA Phase-II, Basani, Jodhpur | | |
| viia Filase-ii, Basaiii, Jouripui | | |
| NIT No | dated: | for Rate |
| Contract | | |
| | | |
| Subject: Manufacturer's Authorization Certificate. | | |
| | | |
| Dear Sir, | | |
| We, | who are prov | en and reputable |
| Manufacturers / Importer of | | |
| description of the Items / Category offered in the Quota | ution) having factories at | (name and |
| | | authorize |
| M/s(name and addres | | |
| further, against your requirement as contained in the | above referred Tender Form for | the above items |
| manufactured by us. | | |
| , | | |
| We further confirm that no supplier or firm or individua | al other than Messrs | |
| (name and address | of the above agent) is authorized to | o submit a tender, |
| process the same further against your requirement as co | | |
| above items manufactured by us. | | |
| | | |
| We also hereby confirm that we would be responsible for | or the satisfactory execution of sup | ply placed on the |
| authorized agent. We also confirm that the price quoted b | y our agent shall not exceed than the | at which we would |
| nave quoted directly. | | |
| | | Yours faithfully, |
| | [Signature with date, nam | e and designation |
| | , | <i>,</i> |
| | For and on behalf of Messrs. | |
| | | |
| | [Name, address & contact detail of | tne manufacturer] |

Note:

- 1. Manufacturer's Authorization Certificate format other than this format will not be acceptable.
- 2. This letter of Manufacturer's Authorization Certificate should be on the Letter Head of the Original Manufacturing firm and should be signed by a person competent and having the power of attorney to legally bind the manufacturer.

ANNEXURE-III [TENDER ACCEPTANCE FORM]

To The Executive Director, All India Institute of Medical Sciences, Jodhpur MIA Phase-II, Basani, Jodhpur _____ dated: _____ for Rate Contract at AIIMS Jodhpur. We, the undersigned have examined the above mentioned Tender Enquiry Document, including amendment / corrigendum (if any), the receipt of which is hereby confirmed. We now offer to supply and deliver in conformity with your above referred document for the sum as shown in the Price Schedules (BoQ) uploaded herewith and made part of this bid. If our bid is accepted, we undertake to supply the items for which Rate Contract has been concluded, in accordance with the delivery schedule as specified in the Schedule of Requirements. We further confirm that, if our bid is accepted, we shall provide you with a Performance Security of required amount in an acceptable form as mentioned in your NIT.

We agree to keep our bid valid for acceptance as required in your NIT Document, subsequently for the extended period, if any, agreed to by us. We also accordingly confirm to abide by this bid up to the aforesaid period. We further confirm that, until a formal Rate Contract is executed, this bid read with your written acceptance thereof within the aforesaid period shall constitute a binding contract between us.

We further understand that you are not bound to accept the lowest or any bid you may receive against your abovereferred advertised tender enquiry.

We confirm that we do not stand deregistered/banned/blacklisted by Central / State Govt. / PSU / Autonomous Bodies etc.

We confirm that we fully agree to the terms and conditions specified in the Tender Enquiry Document, including amendment / corrigendum if any.

We hereby certify that if at any time, information furnished by us is proved to be false or incorrect, we are liable fo

| for any action as deemed fit by | AllMS Jodhpur in addition to forfeiture of the Bid Security / Performance Security. |
|---------------------------------|---|
| | Name: |
| | (Signatures of the Bidder with Name, Designation & Company's Seal) |
| | Address: |
| | |
| | |
| Place: | |
| Date: | |
| Date: | |

ANNEXURE-IV [NON-BLACKLISTING CERTIFICATE]

| То | | |
|---|---|--|
| The Executive Director, | | |
| All India Institute of Medical Sciences, Jod | lhpur | |
| MIA Phase-II, Basani, Jodhpur | | |
| | | |
| | dated: | |
| Contract | | _ at AIIMS Jodhpur. |
| (i) I/We hereby certify that the [Nam Central / State Government / Public Secto | ne of the company / firm] has not been ever blacklor Undertaking / Institute on any account. | isted/debarred by any |
| • | tion given in bid is true and correct in all aspects an are false and incorrect, the contract may be summa ny action as per NIT rules. | • |
| | OR | |
| (Name of Central / Sta Nodated However, blacklisting/debarment has been revoked | [Name of the company / firm] has been deleate Government / Public Sector Undertaking / I/We(Name of the company / firvide order Nodatedof the company / firm) is not blacklisted/debarred / Institute on any account. | Institute) vide order rm) state that the said I certify that as or |
| • | tion given in bid is true and correct in all aspects an are false and incorrect, the contract may be summa ny action as per NIT rules. | • |
| [Note: Strike out whichever is not applical | ble] | |
| | Name: | |
| | (Signatures of the Bidder with Name, Designat | ion & Company's Seal |
| | Address: | , , |
| | Address | |
| | | |
| | | |
| | | |
| Place: | | |
| Place: | | |
| Date: | | |
| | | |

ANNEXURE-V [NO DEVIATION CERTIFICATE]

| 10 | | |
|--|---|----------------------|
| The Executive Director, | | |
| All India Institute of Medical Sciences, Joc | dhpur | |
| MIA Phase-II, Basani, Jodhpur | | |
| NIT No | dated: | for Rate |
| Contract | at | : AIIMS Jodhpur. |
| | hereby certify that not | |
| • | e in our offer documents, I/We have neither set any ter | |
| • | e conditions of AIIMS Jodhpur's tender specification, e | |
| | s and conditions mentioned in AIIMS Jodhpur's tender any deviation is found in my / our tender documents, A | • |
| take any suitable decision / action against | • | illivis Jouripur may |
| take any suitable decision y decion against | , , Gai | |
| | Name: | |
| | (Signatures of the Bidder with Name, Designation o | & Company's Seal) |
| | Address: | |
| | | |
| | | |
| | | |
| Place: | | |
| Date: | | |
| | | |

ANNEXURE-VI [PRICE JUSTIFICATION CERTIFICATE]

| То | |
|-----------------------------------|--|
| The Executive Director, | |
| All India Institute of Medical Sc | iences, Jodhpur |
| MIA Phase-II, Basani, Jodhpur | |
| NIT No | dated: for Rate |
| | at AIIMS Jodhpur. |
| I/We, M/s | certify that the rates provided are |
| | supplied / quoted these materials to any Government Department / PSU / Institution |
| for lesser than the rates quote | d in the present bid in the last one year. |
| | |
| | Name: |
| | (Signatures of the Bidder with Name, Designation & Company's Seal) |
| | Address: |
| | |
| | |
| | |
| Place: | |
| Date: | |

ANNEXURE-VII [Land Border Declaration]

| То | | |
|--|--|---|
| The Executive Director, | | |
| All India Institute of Medical Sciences, Jodhpur | | |
| MIA Phase-II, Basani, Jodhpur | | |
| NIT No | datad | for Pate |
| NIT No | uateu | at AIIMS Jodhpur. |
| "We have read the clause regarding restrictions on proc border with India; and solemnly certify that we are not registered with the Competent Authority (copy enclosed) regard and are eligible to be considered." | from such a county or, if from su | ch a country, we are |
| | AND | |
| "We have read the clause regarding restrictions on proc border with India and on sub-contracting to contractors f from such a county or, if from such a country, we are regi we shall not subcontract any work to a contractor from su Competent Authority. We hereby certify that we fulfil considered." | rom such a country; and solemnly c stered with the Competent Authorit Ich countries unless such contractor | ertify that we are not by (copy enclosed) and be is registered with the |
| It is to declare that if, our bid/offer is accepted by the pur the certificate is to be found as false, this would be groun legal action in accordance with the law may be initiated o | d for immediate termination of our | bid/offer and further |
| | [Signature with date, nar | me and designation] |
| For | and on behalf of M/s | |
| | [Name & address of the Orig | ginal Manufacturer] |
| | | |

ANNEXURE-VIII

[BANK GUARANTEE FORM FOR BID SECURITY (EARNEST MONEY)]

| Whereas | (Name and address | of the |
|---|--|----------|
| Bidder) (hereinafter called the "Bidders") | | |
| | for the supply of | |
| | (hereinafter called the "Bid") | against |
| the purchaser's NIT No | | |
| dated know all persons by | | |
| | having our registered offi | ce at |
| Hereinafter called the "Bank") | | |
| are bound unto AIIMS, Jodhpur | | |
| hereinafter called the "Purchaser") | | |
| , | | |
| n the sum of | for which payment will and truly to be made to t | he said |
| Purchaser, the Bank binds itself, its successors and assign | | |
| said Bank this day of20 | | |
| | | |
| The conditions of this obligation are: | | |
| 1) If the Bidder withdraws or amends, impairs or de | erogates from the bid in any respect within the pe | riod of |
| validity of this Bid. | | |
| 2) If the Bidder having been notified of the acceptanc | e of his Bid by the Purchaser during the period of its v | alidity: |
| a. If the bidder fails or refuses to furnish the perform | ance security for the due performance of the Rate Co | ontract |
| / Purchase Orders or | | |
| b. If the bidder fails or refuses to accept / execute the | e Contract / Purchase orders or | |
| c. If it comes to notice at any time, that the informat | ion / documents furnished in its Bid are false or incor | rect or |
| misleading or forged | | |
| | | |
| We undertake to pay the Purchaser up to the above an | nount upon receipt of its first written demand, with | out the |
| Purchaser having to substantiate its demand, provided | | |
| claimed by it is due to it owing to the occurrence of o | one or more the three conditions, specifying the oc | curred |
| condition(s). | | |
| This guarantee will remain in force upto | linsert date of additional sixty days after Rid Validi | tv) and |
| any demand in respect thereof should reach the Bank r | | ty , and |
| any demand in respect thereof should reach the Bank r | iot later than the above date. | |
| | (Signature with date of the authorized officer of the | Bank) |
| | (0.8.000.000.000.000.000.000.000.000.000 | |
| | (Name and designation of the O | Officer) |
| | | |
| | | |
| (Se | eal, name & address of the Bank and address of the E | Branch) |
| (| | , |

AIIMS — Jodhpur 23 | Page

NOTE: ANNEXURE-VIII is applicable for only those bidders who are submitting their Bid Security in the form of Bank

Guarantee.

ANNEXURE-IX [LIST OF QUOTED ITEMS]

| Contrac | ct | | | | at All | MS Jodhpur. |
|---------|--------------------|-----------|--|-----------------------------|-------------------|---|
| S. No. | Tender Ref. No. | Item Name | Specifications | Accounting Unit / Pack Size | Make (Company) | Whether complying with NIT's Specs (Yes/No) |
| 1. | | | | | | |
| 2. | | | | | | |
| 3. | | | | | | |
| 4. | | | | | | |
| • | | | | | | |
| : | | | | | | |
| | | | | | | |
| | | (Signa | Na Itures of the Bidder with Add | n Name, Desig | | mpany's Seal) |
| Dlaco | | | | | | |

AIIMS - Jodhpur 24 | Page

ANNEXURE-X [Calculation of Local Content]

(To be submitted along with BoQ)

| То | | | | |
|-----------------------------|----------------------|----------------------|-----------------------------|--------------------------|
| The Executive Director, | | | | |
| All India Institute of Medi | cal Sciences, Jodhpu | ır | | |
| MIA Phase-II, Basani, Jodi | npur | | | |
| | | | | |
| NIT No. | | | dated: | for Rate |
| Contract | | | | |
| | | | | |
| Name of | Calculation by Ma | anufacturer | | |
| Manufacture | (Cost per unit of | | | |
| Cost Component | | Cost (Imported | Total Cost (INR/ US | Percentage of Local |
| · | Component) | Component) | \$) | Content |
| | Α | В | C=a+b | D=(a/c)*100 |
| l | | | | |
| II | | | | |
| III. Total Cost | | | | |
| (Excluding tax and du | ities) | | | |
| Note:- | | | | |
| I. Cost (Domestic | Component): Sum | of the costs of all | l inputs which go into | the product (including |
| duties and taxes levied | on procurement | of inputs except t | hose for which credit | t/ set-off can be taken) |
| which have not been in | nported directly or | through a domest | ic trader or an interm | ediary. |
| II. Cost (Imported | Component): Sum | of the costs of all | l inputs which go into | the product (including |
| duties and taxes levied | on procurement o | f inputs except the | se for which credit/ s | et-off can be taken). |
| | • | | , | , |
| | | | | |
| | | | Name: | |
| | | (Cianatures of the P | iddar with Nama Dasia | nation & Company's Seal) |
| | | (Signatures of the B | idder with Name, Desig | nation & company's Sear |
| | | | Address: | |
| | | | | |
| | | | | |
| Place: | | | | |
| Date: | · | | | |
| | | | | |
| | | | | |
| | | | | |
| NOTE O L. L. | 10 | | | |
| NOTE: Calculation of Loc | al Content submitted | in the Technical Bio | d will lead to rejection of | the bid. |
| | | | | |

AIIMS - Jodhpur

ANNEXURE-XI

[Affidavit of Self Certification regarding Local Content]

(on ₹ 100/- Non-Judicial Stamp Paper)

| I S/o.D/o,W/o | | |
|-------------------|------------------------------|--|
| Resident of | do hereby solemnly affirm an | |
| declare as under. | | |

That I will agree to abide by the terms and conditions of the policy of Government of India issued vide order no. P-45021/2/2017-B.E.-II dated 15/06/2017.

That the information furnished hereinafter is correct to best of my knowledge and belief and I undertake to produce relevant records before the procuring entity or any authority so nominated by the Government of India for the purpose of assessing the local content.

That the local content for all inputs which constitute the said drugs has been verified by me and I am responsible for the correctness of the claims made therein.

That in the event of the domestic valve addition of the product mentioned herein is found to be incorrect and not meeting the prescribed valve-addition norms, based on Government of India for the purpose of assessing the local content, action will be taken against me as per Order No. P-45021/2/2017-B.E.-II dated 15.06.2017.

I agree to maintain the following information in the Company's record for a period of 8 years and shall make this available for verification to any statutory authorities:

- i) Name and details of the Domestic Manufacturer (Registered Officer, Manufacturing unit location, nature of legal entity)
- ii) Date on which this certificate is issued.
- iii) Medicine for which the certificate is product.
- iv) Procuring entity to whom the certificate is furnished.
- v) Percentage of local content claimed.
- vi) Name and contact details of the unit of the manufacturer.
- vii) Sale Price of the product.
- viii) Ex-Factory Price of the product.
- ix) Freight, insurance and handling.
- x) Total Bill of Material.
- xi) List and total cost valve of inputs used for manufacture of the medicine certificates from suppliers, if the input is not in-house to be attached.
- xii) List and cost of inputs which and imported, directly or indirectly.

For and on behalf of

(Name of firm/ entity)

Authorized signatory (To be duly authorized by the Board of Director)

AIIMS - Jodhpur 26 | Page

ANNEXURE-XII [BANK GUARANTEE FORM FOR PERFORMANCE SECURITY]

(To be submitted by successful bidders only)

| Whereas (Name and ac | ldress of the |
|---|----------------|
| Bidder) (hereinafter called the "the Supplier") has undertaken, in pursuance of NIT No. | |
| dated valid from to | for supply |
| (insert description of goods), (Hereinafter called "the Contract"), to A | IIMS Jodhpur |
| (Hereinafter called "the Purchaser"). | |
| AND WHEREAS it has been stipulated by you in the said contract that the supplier shall furnish you | ı with a bank |
| guarantee by a scheduled commercial bank recognized by you for the sum specified therein as | security for |
| compliance with its obligations in accordance with the contract; | |
| AND WHEREAS we have agreed to give the supplier such a bank guarantee; | |
| NOW THEREFORE we hereby affirm that we are guarantors and responsible to you, on behalf of the s | |
| a total of (insert Amo | |
| Performance Security in words and figures), and we undertake to pay you, upon your first written dem the supplier to be in default under the contract and without cavil or argument, any sum or sums without cavil or argument. | _ |
| of (amount of guarantee) aforesaid, without your needing to prove or to show grounds or reasons for | |
| or the sum specified therein. | your acmana |
| | |
| We hereby waive the necessity of your demanding the said debt from the supplier before presentin demand. | g us with the |
| We further agree that no change or addition to or other modification of the terms of the contract to l | oe performed |
| there under or of any of the contract documents which may be made between you and the supplie | - |
| way release us from any liability under this guarantee and we hereby waive notice of any such chang | e, addition or |
| modification. | |
| This guarantee will remain in force up to (insert last date of currency of Contract | plus Warrant |
| Period (If applicable) plus additional Sixty Days) and any demand in respect thereof should reach the I | 3ank not later |
| than the above date. | |
| (Signature with date of the authorized officer of the Bank) | |
| Name and designation of the officer | |
| | |
| Seal, name & address of the Bank and address of the Branch | |

ANNEXURE-XIII [FINANCIAL BID]

BoQ must be uploaded as per instructions given in **Tender Enquiry Document** at CPP Portal.

Note:

- 1. Rates to be quoted for Each Unit / Per Unit of item (without including GST). Not for the Pack / Box etc.
- 2. Rates to be guoted upto TWO DECIMAL Points and in INR Only.
- 3. FDA approved IHC antibodies for cancer diagnosis (ALK-D5F3, ROS1-SP384, PDL1-SP263, SP142, TTF1-SP141, FOLR1, MMR anti-PMS2 (A16-4), antiMSH2 (G219-1129), anti-MSH6 (SP93), anti-BRAF V600E (VE1), anti-MLH1 (M1).

Place:
Date:

Designation:

Contact:

eMail ID: Office Address:

Bidder must submit financial bid in .xls (Excel workbook 97-2003 workbook) only.

ANNEXURE-XIV [LIST OF ITEMS]

| 1. Dep | 1. Department : Biochemistry | | | | |
|--------|------------------------------|---|----------------|--|--|
| Sr. | Tender Ref. No. | Name of Item | Specifications | | |
| 1 | 1.001 | CD3 MS X HU FITC (CLONE HIT3A) | | | |
| 2 | 1.002 | CD4 MS X HU PERCP-CY5.5 (OKT4) | | | |
| 3 | 1.003 | MS IGG1 ISOTYPE CNTRL PERCP | | | |
| 4 | 1.004 | CD3 MS X HU PERCP-CY5.5-OKT3 | | | |
| 5 | 1.005 | CD4 MS X HU APC (CLONE RPA-T4) | | | |
| 6 | 1.006 | CD8A MS X HU PE | | | |
| 7 | 1.007 | CD3 APC-H7 | | | |
| 8 | 1.008 | CD4 V500 | | | |
| 2. Dep | artment : | Microbiology | | | |
| 9 | 2.001 | Antigen Set for Widal Test | | | |
| 10 | 2.002 | Dengue NS1 Ag Rapid | | | |
| 11 | 2.003 | Dengue NS1 Ag ELISA | | | |
| 12 | 2.004 | Dengue IgM/ IgG Rapid | | | |
| 13 | 2.005 | DENGUE DUO (DENGUE NS1 Ag + IgG/IgM) | | | |
| 14 | 2.006 | Chikungunya IgM Rapid | | | |
| 15 | 2.007 | Chikungunya IgM ELISA | | | |
| 16 | 2.008 | HAV IgM Elisa / Chemi | | | |
| 17 | 2.009 | HBs Ag Rapid | | | |
| 18 | 2.010 | HBs Ag ELISA | | | |
| 19 | 2.011 | HCV Antibody Rapid | | | |
| 20 | 2.012 | HCV Antibody ELISA | | | |
| 21 | 2.013 | HIV1/2 rapid test | | | |
| 22 | 2.014 | HIV 1/2 Rapid test (Qualpro) | | | |
| 23 | 2.015 | HIV1/2 ELISA | | | |
| 24 | 2.016 | Torch Panel (Ab Elisa for Toxo + Rubella + CMV + HSV) | | | |
| 25 | 2.017 | Toxoplasma IgG ELISA | | | |
| 26 | 2.018 | Toxoplasma IgM ELISA | | | |
| 27 | 2.019 | Microfilaria Antigen Rapid Card Test | | | |
| 28 | 2.020 | Leptospira IgM/IgG, Rapid | | | |
| 29 | 2.021 | Leptospira IgM ELISA | | | |
| 30 | 2.022 | Rotavirus Antien, rapid | | | |
| 31 | 2.023 | Chalmydia Antigen rapid | | | |
| 32 | 2.024 | Measles IgG ELISA | | | |
| 33 | 2.025 | Varicella Zoster Virus IgG ELISA / Chemi | | | |
| 34 | 2.026 | Malaria Antigen Rapid (Pan Specific / PF) | | | |
| 35 | 2.027 | MERISCREEN Syphiline | | | |
| 36 | 2.028 | VZV IgM | | | |

| 37 | 2.029 | Brucella Antigenic Suspension (Rose Bengal Test) | |
|----------|-------|---|--|
| 38 | 2.030 | Brucella IgM ELISA | |
| 39 | 2.031 | Brucella IgG ELISA | |
| 40 | 2.032 | Typhoid IgG/IgM Combo Rapid Test | |
| 41 | 2.033 | Anti-streptolysin O (ASO) | |
| 42 | 2.034 | Anti ds-DNA | |
| 43 | 2.035 | Anti PR-3 (c-ANCA) | |
| 44 | 2.036 | Anti-MPO (p-ANCA) | |
| 45 | 2.037 | RPR (Rapid plasma Reagin) for syphilis | |
| 46 | 2.038 | TPHA test for syphilis / TPHA microhemagglutination | |
| 47 | 2.039 | H pylori Stool Ag test | |
| 48 | 2.039 | Stool Occult blood (HAEMTEST) | |
| 49 | 2.040 | Tuberculin PPD for Mantoux test (2TU (Arkray)) | |
| 50 | 2.041 | Copro Clostridium difficile Rapd GDH+ ToxA+ Tox B | |
| 51 | 2.042 | Avidity Toxoplasma gondii IgG ELISA | |
| 52 | 2.044 | Echinococcus IgG ELISA | |
| 53 | 2.045 | Entamoeba histolytica IgG ELISA | |
| 54 | 2.045 | Strongyloides IgG ELISA | |
| 55 | 2.040 | Taenia solium IgG ELISA | |
| | | | |
| 56 | 2.048 | MPT 64 TB Ag rapid test | |
| 57 | 2.049 | Proteus OX-2 Antigen suspension | |
| 58 | 2.050 | Proteus OX-19 Antigen suspension | |
| 59 | 2.051 | Proteus OX-K2 Antigen suspension | |
| 60 61 | 2.052 | Immunofluorescence kit (Scrub typhus- IgM) | |
| 91 | 2.053 | Orientia tsutugamushi IgM ELISA | |
| 62 | 2.054 | Aspergillus Galactomannan lateral Flow Assay (EU/CE approved for semi-quantitative results using a cube | |
| | | reader | |
| 63 | 2.055 | Cryptococcal Antigen latex agglutination System(CALAS) | |
| 64 | 2.056 | MagGreen DNA loading buffer | |
| 65 | 2.057 | Histoplasma capsulatum Urinary antigen rapid test | |
| 66 | 2.058 | Anti- Bordetella pertussis toxin IgG ELISA | |
| 67 | 2.059 | Platelia Aspergillus Antigen Assay | |
| 68 | 2.060 | 2-step Pneumocystis jirovecii IFA Test Kit | |
| 69 | 2.061 | XpressDNA Tissue Kit | |
| 70 | 2.062 | Cryptococcal Lateral Flow Assay (US-FDA approved) | |
| 71 | 2.063 | CMV Cytomegalovirus RT-PCR KIT | |
| 72 | 2.064 | DENGUE SEROTYPE Real PCR kit | |
| 73 | 2.065 | CHIKUNGUNYA VIRUS RT-PCR | |
| 74 | 2.066 | BK VIRUS BKV Real-time PCR Kit | |
| 75 | 2.067 | EBV Real-time PCR Kit | |
| 76 | 2.068 | HBV VIRUS HBV Real-time PCR Kit | |
| 77 | 2.069 | HCV VIRUS HCV Real-time PCR Kit | |
| 78 | 2.070 | JE VIRUS JEV Japanese encephalitis RT PCR Kit | |
| 79 | 2.071 | VZV VIRUS Varicella zoster virus RT PCR Kit | |
| 79 | 2.0/1 | VZV VINOS VAIICEIIA ZOSLEI VIIUS KI PCK KIL | |

| 80 | 2.072 | WNV VIRUS West Nile Virus RT PCR Kit |
|-----|-------|--|
| 81 | 2.073 | RSV Respiratory syncytial virus A & B RT PCR Kit |
| 82 | 2.074 | ENTEROVIRUS Enterovirus Real-time PCR Kit |
| 83 | 2.075 | PARVO B19-VIRUS RT-PCR KIT |
| 84 | 2.076 | HSV-1& HSV-2 genotyping RT PCR Kit |
| 85 | 2.077 | Dengue/Chikungunya Detection Real Time PCR Kit |
| 86 | 2.078 | H1N1/H3N2 WITH INF-B Real Time PCR Kit |
| 87 | 2.079 | Hepatitis E Virus (HEV) qPCR kit |
| 88 | 2.080 | Hepatitis A Virus (HAV) qPCR kit |
| 89 | 2.081 | HAV/HEV - Real Time PCR kit Multiplex |
| 90 | 2.082 | HPV genotyping real time PCR |
| 91 | 2.083 | CCHFV RTPCR Kit |
| 92 | 2.084 | Foot & Mouth Disease Virus RT-PCR kit |
| 93 | 2.085 | Astrovirus Real-Time PCR kit |
| 94 | 2.086 | Coxsackievirus A16 (CA16) Real-Time PCR kit |
| 95 | 2.087 | Measles Virus Real-Time PCR kit |
| 96 | 2.088 | Norovirus & Rotavirus Real-Time PCR kit |
| 97 | 2.089 | Rubella & Measles Virus Real-Time PCR kit |
| 98 | 2.090 | BK/JC virus RT PCR kit |
| 99 | 2.091 | Anti-HBeAg ELISA test |
| 100 | 2.092 | Anti-HBeAb ELISA test |
| 101 | 2.093 | Anti-HBc IgM ELISA test |
| 102 | 2.094 | Anti-HBsAb ELISA test |
| 103 | 2.095 | Dengue IgM ELISA test |
| 104 | 2.096 | Measles IgM ELISA test |
| 105 | 2.097 | WEST Nile IgM ELISA test |
| 106 | 2.098 | EBV(Epstein Barr Virus) IgM ELISA test |
| 107 | 2.099 | EBV (Epstein Barr Virus) IgG ELISA test |
| 108 | 2.100 | Adenovirus IgM ELISA test |
| 109 | 2.101 | ParvoB19 IgM Virus ELISA test |
| 110 | 2.102 | Mumps IgM Virus ELISA test |
| 111 | 2.103 | Mumps IgG Virus ELISA test |
| 112 | 2.104 | Fecal Rotavirus Antigen ELISA test |
| 113 | 2.105 | Rabies IgG ELISA test |
| 114 | 2.106 | Adenovirus IgG ELISA test |
| 115 | 2.107 | Dengue IgG ELISA test |
| 116 | 2.108 | HDV IgG ELISA test |
| 117 | 2.109 | HDV IgM ELISA test |
| 118 | 2.110 | ToRCH pannel rapid test |
| 119 | 2.111 | COVID IgG ELISA Test |
| 120 | 2.112 | COVID real time pcr |
| 121 | 2.113 | Covid Ag Rapid test |
| 122 | 2.114 | Rubella IgG ELISA test |
| 123 | 2.115 | Rubella IgM ELISA test |

| 124 | 2.116 | CMV IgG ELISA test | |
|-----|-------|--|--|
| 125 | 2.117 | CMV IgM ELISA test | |
| 126 | 2.118 | HSV 1/2 IgM ELISA test | |
| 127 | 2.119 | HSV1/2 IgG ELISA test | |
| 128 | 2.120 | HEV IgM by ELISA test | |
| 129 | 2.121 | Trepolisa 3.0 (Treponemal Ab ELISA kit) | |
| 130 | 2.122 | STD Panel Real Time PCR kit/ Multiplex STD Detection Kit | |
| 121 | 2 122 | Respiratory Pathogen Panel Kit/ Real Time PCR | |
| 131 | 2.123 | respiratory Pathogen | |
| 132 | 2.124 | Chlamydia trachomatis and Neisseria gonorrhoeae | |
| | | Detection Real Time PCR detection Kit | |
| 133 | 2.125 | Mutiplex real Time PCR kit for Vaginitis Pathogens detection | |
| 134 | 2.126 | Xpert CT/NG | |
| + | 2.120 | DNA extraction kit | |
| 135 | | | |
| 136 | 2.128 | Hotstar Taq plus mastermix | |
| 137 | 2.129 | Molecular biology consumables Salmonella Antisera | |
| 138 | 2.130 | | |
| 139 | 2.131 | Shigella antisera | |
| 140 | 2.132 | Vibrio antisera | |
| 141 | 2.133 | FISH, RT PCR automation systems, probes | |
| 142 | 2.134 | Rickettsial serology kits (Rickettsia Conorii Elisa) | |
| 143 | 2.135 | Proteus antigen (weil felix kit) | |
| 144 | 2.136 | Rickettsial immunofluorescence kits | |
| 145 | 2.137 | Fungal Real time PCR kits | |
| 146 | 2.138 | Coxiella serology kits / Coxiella Burnetti (Q-Fever phase 1 lgG) | |
| 147 | 2.139 | Fungal serology kits | |
| 148 | 2.140 | Anti Rabies nucleocapside Conjugate | |
| 149 | 2.141 | Clostridium difficile Toxin ELISA kit | |
| 150 | 2.142 | Clostridium difficile GDH ELISA kit | |
| 151 | 2.143 | Carbapenem resistance Detection Kit/ Real-Time PCR Kit | |
| | | for Carbapenemase Genes Detection | |
| 152 | 2.144 | Bacterial pneumonia Detection Panel/ Real time PCR kit | |
| 153 | 2.145 | Streptococcus pneumoniae antigen detection Test Kit | |
| 154 | 2.146 | Meningitis Bacterial Antigen Test Kit | |
| 155 | 2.147 | ANA Screen ELISA / EIA ANA Screen kit | |
| 156 | 2.148 | Anti-CCP II ELISA | |
| 157 | 2.149 | LINE IMMUNO ASSAY KITS | |
| 158 | 2.150 | Syndromic Real Time Multiplex PCR kits | |
| 159 | 2.151 | Nucleic Acid Extraction Kits | |
| 160 | 2.152 | Protein Extraction Kits | |
| 161 | 2.153 | Aspergillus urinary antigen lateral flow assay | |
| 162 | 2.154 | Real-time PCR kits for fungal diagnostics (Mucor, Aspergillus, Dermatophytes, Pneumocystis, Candida) | |

| 163 | 2.155 | Calcofluor white fluorescent dye | |
|--------|------------|--|--|
| 164 | 2.156 | QuantiFERON TB Gold ELISA kits | |
| 165 | 2.157 | CyTB Antigen for CyTB skin Test | |
| 166 | 2.158 | Clostridium tetani toxin IgG ELISA kit | |
| 167 | 2.159 | GeneXpert cartridge for Clostridium difficile | |
| 168 | 2.160 | Cryptosporidium ELISA | |
| 169 | 2.161 | Cysticercosis ELISA | |
| 170 | 2.162 | DNA sequencing (Sanger) | |
| 171 | 2.163 | Primer designing (both for conventional & real-time PCR) | |
| 172 | 2.164 | Anti IgG Antibody ELISA for Pertussis | |
| 173 | 2.165 | Clostridium botulinum toxin IgG ELISA kit | |
| 3. Dep | t: Patholo | ogy & Lab. Medicine | |
| 174 | 3.001 | AAT (α-1 Antitrypsin) | |
| 175 | 3.002 | ABCB-11 | |
| 176 | 3.003 | ABCB-4 | |
| 177 | 3.004 | ACTH | |
| 178 | 3.005 | Adipophilin | |
| 179 | 3.006 | AFP | |
| 180 | 3.007 | Albumin | |
| 181 | 3.008 | ALK | |
| 182 | 3.009 | Alkaline Phosphatase | |
| 183 | 3.010 | AMAC-R | |
| 184 | 3.011 | AMYLOID-A | |
| 185 | 3.012 | Androgen Receptor | |
| 186 | 3.013 | Annexin A1 | |
| 187 | 3.014 | ANTI-PLA 2R | |
| 188 | 3.015 | ANTI-THSD7A | |
| 189 | 3.016 | Arginase 1 | |
| 190 | 3.017 | Aspergillus | |
| 191 | 3.018 | ATM | |
| 192 | 3.019 | ATRX | |
| 193 | 3.020 | B72.3 | |
| 194 | 3.021 | B7H3 | |
| 195 | 3.022 | BAG 3 | |
| 196 | 3.023 | BAP1 | |
| 197 | 3.024 | Bcl-2 | |
| 198 | 3.025 | Bcl-6 | |
| 199 | 3.026 | BCOR | |
| 200 | 3.027 | Ber EP4 | |
| 201 | 3.028 | Beta Catenin | |
| 202 | 3.029 | Beta Follicle Stimulating Hormone (FSH) | |
| 203 | 3.030 | Beta Luteinizing Hormone (LH) | |
| 204 | 3.031 | BETA-HCG | |
| 205 | 3.032 | BOB-1 | |

| 206 | 3.033 | BRACHYURY | |
|-----|-------|-------------------------|--|
| 207 | 3.034 | BrafV600E | |
| 208 | 3.035 | BRG1 | |
| 209 | 3.036 | BSEP | |
| 210 | 3.037 | C4d | |
| 211 | 3.038 | C5b-9 (MAC) | |
| 212 | 3.039 | CA125 | |
| 213 | 3.040 | CA19-9 | |
| 214 | 3.041 | CALCITONIN | |
| 215 | 3.041 | CALDESMON H | |
| 216 | 3.042 | CALML5 | |
| 217 | | | |
| _ | 3.044 | Calgadiaia | |
| 218 | 3.045 | CAME 2 | |
| 219 | 3.046 | CAM5.2 | |
| 220 | 3.047 | CAMTA | |
| 221 | 3.048 | CARBONIC ANHYDRASE CAIX | |
| 222 | 3.049 | CATHEPSIN | |
| 223 | 3.050 | CD-3 | |
| 224 | 3.051 | CD10 | |
| 225 | 3.052 | CD103 | |
| 226 | 3.053 | CD117 | |
| 227 | 3.054 | CD-138 | |
| 228 | 3.055 | CD-15 | |
| 229 | 3.056 | CD-16 | |
| 230 | 3.057 | CD19 | |
| 231 | 3.058 | CD1a | |
| 232 | 3.059 | CD2 | |
| 233 | 3.060 | CD-20 | |
| 234 | 3.061 | CD21 | |
| 235 | 3.062 | CD22 | |
| 236 | 3.063 | CD23 | |
| 237 | 3.064 | CD25 | |
| 238 | 3.065 | CD30 | |
| 239 | 3.066 | CD-31 | |
| 240 | 3.067 | CD33 | |
| 241 | 3.068 | CD-34 | |
| 242 | 3.069 | CD35 | |
| 243 | 3.070 | CD38 | |
| 244 | 3.071 | CD4 | |
| 245 | 3.072 | CD41 | |
| 246 | 3.073 | CD-43 | |
| 247 | 3.074 | CD45 | |
| 248 | 3.075 | CD5 | |
| 249 | 3.076 | CD56 | |
| 250 | 3.077 | CD61 | |
| 230 | 3.077 | CD01 | |

| 251 | 3.078 | CD68 | |
|-----|-------|---------------------------|--|
| 252 | 3.079 | CD7 | |
| 253 | 3.080 | CD79a | |
| 254 | 3.081 | CD-8 | |
| 255 | 3.082 | CD-99 | |
| 256 | 3.083 | CDK4 | |
| 257 | 3.084 | CDX2 | |
| 258 | 3.085 | CEA (Polyclonal) | |
| 259 | 3.086 | Chromogranin A | |
| 260 | 3.087 | CK5/6 | |
| 261 | 3.088 | CK7 | |
| 262 | 3.089 | CK8/18 | |
| 263 | 3.090 | CK14 | |
| 264 | 3.091 | CK 20 | |
| 265 | 3.092 | Claudins 3,4,7 | |
| 266 | 3.093 | Clusterin | |
| 267 | 3.094 | CMV | |
| 268 | 3.095 | C-myc | |
| 269 | 3.096 | COLLAGEN IV | |
| 270 | 3.097 | Cortactin | |
| 271 | 3.098 | Cyclin D1 | |
| 272 | 3.099 | Cytokeratin 19 | |
| 273 | 3.100 | Cytokeratin 8 | |
| 274 | 3.101 | D2 40 | |
| 275 | 3.102 | Desmin | |
| 276 | 3.103 | DOG-1 | |
| 277 | 3.104 | DPC-4, Clone 8 (SMAD4) | |
| 278 | 3.105 | Dysferlin | |
| 279 | 3.106 | Dystrophins | |
| 280 | 3.107 | EBV | |
| 281 | 3.108 | EBV-LMP1 | |
| 282 | 3.109 | E-Cadherin | |
| 283 | 3.110 | EGFR | |
| 284 | 3.111 | EMA | |
| 285 | 3.112 | ER | |
| 286 | 3.113 | ER Beta | |
| 287 | 3.114 | ETV4 | |
| 288 | 3.115 | Factor XIIa | |
| 289 | 3.116 | Fascin | |
| 290 | 3.117 | Fli-1 | |
| 291 | 3.118 | Follicular dendritic cell | |
| 292 | 3.119 | FOXL1 | |
| 293 | 3.120 | FUMARATE HYDRATASE | |
| 294 | 3.121 | GAB1 | |
| 295 | 3.122 | Galectin | |

| 296 | 3.123 | GATA3 | |
|-----|-------|-----------------------|--|
| 297 | 3.124 | GCDFP15 | |
| 298 | 3.125 | GFAP | |
| 299 | 3.126 | Glut 1 | |
| 300 | 3.127 | GLUTAMINE SYNTHETASE | |
| 301 | 3.128 | GLYCOPHORIN | |
| 302 | 3.129 | Glypican-3 | |
| 303 | 3.130 | Granzyme B | |
| 304 | 3.131 | Growth hormone | |
| 305 | 3.132 | H3G34R/V | |
| 306 | 3.133 | H3k27M | |
| 307 | 3.134 | HBME1 | |
| 308 | 3.135 | HELICOBACTER PYLORI | |
| 309 | 3.136 | Hep B Core antigen | |
| 310 | 3.137 | Hep B surface antigen | |
| 311 | 3.138 | Hep-Par-1 | |
| 312 | 3.139 | HER-2 NEU | |
| 313 | 3.140 | HHV-8 | |
| 314 | 3.141 | HMB-45 | |
| 315 | 3.142 | HMWCK | |
| 316 | 3.143 | HPV | |
| 317 | 3.144 | IDH 1 (R132H Clone) | |
| 318 | 3.145 | IgG4 | |
| 319 | 3.146 | INHIBIN- α | |
| 320 | 3.147 | INI-1 (BAF47) | |
| 321 | 3.148 | INSM1 | |
| 322 | 3.149 | INSULIN | |
| 323 | 3.150 | K Light Chain | |
| 324 | 3.151 | Ki-67 | |
| 325 | 3.152 | LAMBDA | |
| 326 | 3.153 | LEF 1 | |
| 327 | 3.154 | Luteinising hormone | |
| 328 | 3.155 | Macrophage | |
| 329 | 3.156 | Mammaglobin | |
| 330 | 3.157 | MAP2 | |
| 331 | 3.158 | Mast Cell Tryptase | |
| 332 | 3.159 | MDM2 | |
| 333 | 3.160 | MELAN-A | |
| 334 | 3.161 | Merosin | |
| 335 | 3.162 | Mesothelin | |
| 336 | 3.163 | MLH1 | |
| 337 | 3.164 | MMP13 | |
| 338 | 3.165 | MMP9 | |
| 339 | 3.166 | MOC31 | |
| 340 | 3.167 | MPO | |

| 341 | 3.168 | MSH2 | |
|-----|-------|-----------------------|----------|
| 342 | 3.169 | MSH6 | |
| 343 | 3.170 | MUC 2 | |
| 344 | 3.171 | MUC 5AC | |
| 345 | 3.172 | MUM-1 | |
| 346 | 3.173 | MuscSpecAct | |
| 347 | 3.174 | MYB | |
| 348 | 3.175 | Myo D1 | |
| 349 | 3.176 | Myogenin | |
| 350 | 3.177 | MYOGLOBIN | |
| 351 | 3.178 | Myosin | |
| 352 | 3.179 | Napsin A | |
| 353 | 3.180 | Neu-N | |
| 354 | 3.181 | NFP | |
| 355 | 3.182 | NKX 2.2 | |
| 356 | 3.183 | NKX3.1 | |
| 357 | 3.184 | NR4A3 | |
| 358 | 3.185 | NSE | |
| 359 | 3.186 | Nut MI | |
| 360 | 3.187 | Oct-4 | |
| 361 | 3.188 | Olig 2 | |
| 362 | 3.189 | P 53 | |
| 363 | 3.190 | P 63 | |
| 364 | 3.191 | P16 | |
| 365 | 3.192 | P40 | |
| 366 | 3.193 | p57/Kip2 | |
| 367 | 3.194 | Pan CK | |
| 368 | 3.195 | PanTRK | |
| 369 | 3.196 | Pap | |
| 370 | 3.197 | Parafibromin | |
| 371 | 3.198 | PAX2 | |
| 372 | 3.199 | PAX5 | |
| 373 | 3.200 | PAX8 | |
| 374 | 3.201 | PDL1 | |
| 375 | 3.202 | Perforin | |
| 376 | 3.203 | PHH3 | |
| 377 | 3.204 | PHOX2B | |
| 378 | 3.205 | Pit- 1 | |
| 379 | 3.206 | PLAG1 | |
| 380 | 3.207 | PLAP | - |
| 381 | 3.208 | PMS2 | |
| 382 | 3.209 | Pneumocystis jiroveci | |
| 383 | 3.210 | PR | |
| | | 1 | . |
| 384 | 3.211 | PRAME | |

| 386 | 3.213 | Prostein |
|-----|-------|--|
| 387 | 3.214 | PSA |
| 388 | 3.215 | Rb Retinoblastoma1 |
| 389 | 3.216 | Renal cell Carcinoma Marker |
| 390 | 3.217 | S-100 |
| 391 | 3.218 | Sarcoglycan α , β , γ , δ or ϵ) |
| 392 | 3.219 | SALL4 |
| 393 | 3.220 | SAT B2 |
| 394 | 3.221 | SDHB |
| 395 | 3.222 | Serotonin |
| 396 | 3.223 | SF-1 |
| 397 | 3.224 | SMA |
| 398 | 3.225 | SMAD4 |
| 399 | 3.226 | Smoothelin |
| 400 | 3.227 | Somatostatin receptor2 SSTR2 |
| 401 | 3.228 | SOX10 |
| 402 | 3.229 | SOX11 |
| 403 | 3.230 | SOX-2 |
| 404 | 3.231 | Stanniocalcin |
| 405 | 3.232 | STAT6 |
| 406 | 3.233 | SV40 Tag |
| 407 | 3.234 | SYNAPTO |
| 408 | 3.235 | TDT |
| 409 | 3.236 | TFE-3 |
| 410 | 3.237 | Thyroglobulin |
| 411 | 3.238 | TIA-1 |
| 412 | 3.239 | TIMP1 |
| 413 | 3.240 | Tissue transglutaminase (tTg) |
| 414 | 3.241 | TLE 1 |
| 415 | 3.242 | TPIT |
| 416 | 3.243 | TRAP |
| 417 | 3.244 | Tri Methyle HIST |
| 418 | 3.245 | TRPS1 |
| 419 | 3.246 | TSH |
| 420 | 3.247 | TTF-1 |
| 421 | 3.248 | Uroplakin |
| 422 | 3.249 | VEGF |
| 423 | 3.250 | Villin |
| 424 | 3.251 | Vimentin |
| 425 | 3.252 | VWF |
| 426 | 3.253 | WT-1 |
| 427 | 3.254 | YAP1 |
| 428 | 3.255 | ZAP-70 |

| 4. Dep | t: Transfusi | on Medicine and Blood Bank | |
|--------|--------------|--|---|
| 429 | 4.001 | Anti A Antisera, monoclonal, WHO and NIB certified for blood bank use, DG registered | Antisera must be appropriate for microplate and tube technique. Must be monoclonal antibody. Should give clear positive reactions with cells bearing the corresponding antigen. Should give clear negative reactions with cells without the corresponding antigen. Should not haemolyse the cells. Should not produce rouleaux. Avidity (time to positive reaction) less than 4 sec. Titre: 256 or more. Must be evaluated and approved by NIB. |
| 430 | 4.002 | Anti B Antisera, monoclonal, WHO and NIB certified for blood bank use, DG registered | 1. Antisera must be appropriate for microplate and tube technique.2. Must be monoclonal antibody.3. Should give clear positive reactions with cells bearing the corresponding antigen.4. Should give clear negative reactions with cells without the corresponding antigen.5. Should not haemolyse the cells.6. Should not produce rouleaux.7. Avidity (time to positive reaction) less than 4 sec.8. Titre: 256 or more.9. Must be evaluated and approved by NIB. |
| 431 | 4.003 | Anti D IgM + IgG (Monoclonal Blend, low protein) | Antisera must be appropriate for microplate and tube technique Should be blend of IgG and IgM monoclonal antibody Should give clear positive reactions with cells bearing the corresponding antigen Should give clear negative reactions with cells without the corresponding antigen Should not haemolyse the cells. Should not produce rouleaux Avidity 10 seconds-20 seconds Titre: 32-64 at room temperature and 128-256 at 37 degree C Must be evaluated and approved by NIB |

AIIMS - Jodhpur 39 | Page

| 433 | 4.005 | Anti D IgG (Human polyclonal, low protein), capable of detecting weak D and partial D | Should not produce rouleaux Avidity less than 10 sec ((10 seconds-20 seconds)) Titre: 128 or more (128-256 at 37 degree C) Must be evaluated and approved by NIB Antisera must be appropriate for microplate and tube technique Should be human polyclonal antibody Should give clear positive reactions with cells bearing the corresponding antigen Should give clear negative reactions with cells without the corresponding antigen Should not haemolyse the cells. Should not produce rouleaux Avidity should not be more than 60 sec Titre: 32-64 at 37 degree C at AHG) Must be evaluated and approved by NIB |
|-----|-------|---|--|
| 434 | 4.006 | Blend of IgM anti D and + Polyclonal IgG (low protein) | 1. Antisera must be appropriate for microplate and tube technique2. Should be blend of IgG and IgM monoclonal antibody3. Should give clear positive reactions with cells bearing the corresponding antigen4. Should give clear negative reactions with cells without the corresponding antigen5. Should not haemolyse the cells.6. Should not produce rouleaux7. Avidity 10 seconds-20 seconds8. Titre: 32-64 at room temperature and 128-256 at 37 degree C9. Must be evaluated and approved by NIB |

| 435 | 4.007 | AHG Antisera, monoclonal, monospecific anti IgG (Anti-Gamma heavy chain) | Antisera must be appropriate for microplate and tube technique Should give clear positive reactions with appropriately sensitised cells Should give clear negative reactions with unsensitised cells Should not haemolyse the cells. Should not produce rouleaux Titre: for monospecific anti-lgG=64 with sensitised cells Must be evaluated and approved by NIB and IVD (EC) |
|-----|-------|--|---|
| 436 | 4.008 | AHG Anti C3d monoclonal | Antisera must be appropriate for microplate and tube technique Should give clear positive reactions with appropriately sensitised cells Should give clear negative reactions with unsensitised cells Should not haemolyse the cells. Should not produce rouleaux Titre: for monospecific Anti C3d minimum 4 Must be evaluated and approved by NIB and IVD (EC) |
| 437 | 4.009 | AHG gel cards (Polyspecific) | 1. Cassettes/cards should have pre filled Gel impregnated with polyspecific (blend anti IgG& anti c3d) Anti-human globulin for performing cross matching and coombs tests 2. Should be NIB and IVD (EC) approved 3. Should provide gel card centrifuge & incubator free of cost along with card. (Same gel card centrifuge may be used in case AHG & grouping cards are from same vendor) |
| 438 | 4.010 | AHG gel cards (Monospecific for IgG) | 1. Cassettes/cards should have pre filled Gel impregnated with mono-specific anti IgG Anti-human globulin for performing cross matching and coombs tests2. Should be NIB and IVD (EC) approved3. Should provide gel card centrifuge & incubator free of cost along with card.(Same gel card centrifuge may be used in case AHG & grouping cards are from same vendor) |
| 439 | 4.011 | Blood Grouping Gel cards | 1.Cassettes/cards should have pre filled Gel impregnated with grouping sera 2. Should be NIB and IVD (EC) approved 3. Should provide gel card centrifuge & incubator free of cost along with card. (Same gel card centrifuge & incubator may be used in case AHG & grouping cards from same vendor) |

| 440 | 4.012 | Reagent Red cells for antibody screen (three or two cell panel) | Should be ready for use 3%-5% suspension for gel method Two to three pure reagent cells (not blend), which should include one R1R1 and one R2R2 cells Should be able to screen for antibodies against all clinically significant antigens endemic in Asia (including Mia). Should have shelf life of minimum 3 months (at least 45 days from date of delivery at AIIMS Jodhpur Blood Bank). Should be NIB and European IVD EC approved |
|-----|-------|--|--|
| 441 | 4.013 | Reagent Red cell panels (eleven cell panel) for antibody identifiction | Should be ready for use 3%-5% suspension for gel method Panel 11 or more completely phenotyped red cells Should include all clinically significant antigens endemic in India Should include homozygous Jka&Jkb cells. Should include homozygous Jka&Jkb cells. (Fya&Fyb) Should have shelf life of minimum 3 months (at least 35 days from date of supply). Should be NIB and European IVD EC approved. |
| 442 | 4.014 | LISS (Low Ionic Strength Saline Solution) | Should be from the same manufacturer who provides the AHG gel card Should preferably have pH 6.65–6.85 at 21-23°C Conductivity should be 3.5–3.8 mS/cm Osmolality should be 270–305 mOsmol/kg Should be IVD approved for immunohematologic tests. |
| 443 | 4.015 | Anti A1 (Dolichosbifloruslectin) | 1. Ready to useDolichosbiflorusLectin solution2. Should give 2-3+ reaction with 2 seconds for most normal A1 cells and clearly no reaction with A2 cells and O cells3. Should have a titre of at least 1:8 for A1 cells and 1:4 for A1B4. Should not hemolyse or form roleaux5. Should be Approved by NIB for specific blood bank use for A1/A2 discrimination |
| 444 | 4.016 | Anti H (Ulexeuropeuslectin) | Ready to useUlexeuropaeusLectin solution Should give 4+ reaction with 3 seconds for most normal O cells and clearly no reaction with Bombay cells. Should have a titre of at least 1:8 for O cells Should not hemolyse or form roleaux Should be Approved by NIB for specific blood bank use |

| 445 | 4.017 | Anti A, B antibody | Antisera must be appropriate for microplate and tube technique Must be monoclonal antibody Should give clear positive reactions with cells bearing the corresponding antigen Should give clear negative reactions with cells without the corresponding antigen Should not haemolyse the cells. Should not produce rouleaux Avidity (time to positive reaction) less than 4 sec. Titre: 256 or more Must be evaluated and approved by NIB |
|-----|-------|----------------------------|---|
| 446 | 4.018 | Antibody elution kit | Ready to use kit for elution of antibodies coated onto Red cells for the purpose of antibody identification after a positive DAT test. Should be CE and IVD approved for immunohematologic testing purpose Should have shelf life of more than 1.5 years from the date of supply. |
| 447 | 4.019 | PH measuring strips | Should include readymade color-coded pH strips |
| 448 | 4.020 | ELISA kits for HBsAg tests | Wells coated with two or more monoclonal anti HBs (murine and human origin) Should detect all subtypes e.g. ad, ay, etc and variants and mutants Ultra-sensitive assay having Sensitivity < 0.1 ng/ml Should be compatible with automated as well as manual ELISA technique Sensitivity should be over 99.9 % of WHO and NIB panels. Specificity should be over 99.8 %. TMB Substrate should be stable over 4 hours at 15-30°C. The kits should be CE- marked and IVD approved Must be evaluated and approved by NIB |
| 449 | 4.021 | ELISA KITS for HCV tests | 1. Wells coated with synthetic peptide including NS 3, NS 4, NS 5.2. Sensitivity should be over 99.8% of WHO and NIB panels.3. Specificity should be over 99.8%.4. Should be compatible with automated as well as manual ELISA5. Studies with PCR correlation for specificity and sensitivity6. TMB Substrate should be stable over 4 hours at 15-30°C.7. The kits should be CE- marked and IVD approved8. Must be evaluated and approved by NIB |

| 450 | 4.022 | ELISA Kits for HIV 1, HIV 2 and P24 Test. (4 th Generation) | Kit should detect HIV -1, HIV-2, HIV- O and Antigen P24 simultaneously Indirect or competitive inhibition ELISA Kit. Should be compatible with automated as well as manual ELISA One step procedure with specificity of 99 % and Sensitivity should be over 99.9 % of WHO and NIB panel. TMB Substrate should be stable over 4 hours at 15-30°C. The kits should be CE- marked and IVD approved |
|-----|-------|---|---|
| 451 | 4.023 | Rapid Kit For HBsAg Tests | Should be immunoassay/capture principle Should be lateral flow device Should have in built quality control band or dot Should have short interpretation time not more than minutes Should have specificity and sensitivity of 100 % Must be evaluated and approved by NIB |
| 452 | 4.024 | Rapid Kit For HCV Tests | Should be 3rd generation Should have antigen immobilised on immunofiltration membrane Should have in built quality control band or dot Should have short interpretation time not more than 30 minutes Should have specificity and sensitivity of 100 % Must be evaluated and approved by NIB |
| 453 | 4.025 | Rapid Kit For HIV1 and HIV2 Tests | Should be based on immunofiltration membrane (flow through) Should have antigen immobilised on immunofiltration membrane Should be 04th Generation i.e. include detection of HIV1 p24 Ag in addition to HIV 1 & 2 Ab. Should have in built quality control band or dot Should have short interpretation time not more than 30 minutes Should have specificity and sensitivity of 100 % Should be approved and evaluated by NIB |
| 454 | 4.026 | Rapid Malaria Antigen detection kit, Panspecific, pLDH based, should be certified by WHO, and NIB for blood bank screening purpose | 1. Should be based on pLDH antigen detection on plastic cassette (not dipstick)2. Should be Approved by WHO and NIB for Blood Bank screening use.3. Pan specific band should detect all species endemic in India and additional species specific bands may be there.4. Sensitivity of the kit at least 95% of P. falciparum infection/cases at 200 parasites per μl of blood and higher at higher parasite density.5. Should be stable at temperatures up to 40°C, wrapped individually to protect from moisture and supplied along with a dropper and dessicant. |

| 455 | 4.027 | RPR (Rapid plasma Reagin) for Syphilis, should be certified by WHO, and NIB for blood bank screening purpose (Non Treponemal Test Principle) | Should be certified by WHO and NIB for blood bank screening purposes. Should be based on modified VDRL antigen (balanced quantities of cardiolipin, lecithin and cholesterol) combined with charcoal particles Flocculation should be macroscopically visible Non Treponemal Test Principle |
|-----|-------|--|--|
| 456 | 4.028 | Antihuman globulin antisera (AHG) Polyspecific (Anti-IgG + Anti C3d) | Antisera must be appropriate for microplate and tube technique Should give clear positive reactions with appropriately sensitised cells Should give clear negative reactions with unsensitised cells Should not haemolyse the cells. Should not produce rouleaux Titre: For polyspecific minimum 64 for IgG and minimum 4 for C3d; Must be evaluated and approved by NIB and IVD (EC) |
| 457 | 4.029 | Monospecific Direct coombs Gel cards | Monospecific IgG, IgM, IgA, C3c, C3d Should provide gel card centrifuge & incubator free of cost along with card. |
| 458 | 4.030 | Monospecific Direct coombs Gel cards (IgG & C3d only) | Monospecific IgG and C3d Should provide gel card centrifuge & incubator free of cost along with card. |
| 459 | 4.031 | Direct coombs IgG1/IgG3 titration cards | 1. Should provide gel card centrifuge & incubator free of cost along with card. |
| 460 | 4.032 | Neutral NACL saline cards | 1. Should provide gel card centrifuge & incubator free of cost along with card. |
| 461 | 4.033 | ADAMTS 13 ELISA KIT (quantitative, activity, autoantibody) | Should detect, quantify the activity of ADAMTS 13 Preferably Ultra-sensitive assay Should be compatible with automated as well as manual ELISA technique Should meet WHO/ NIB panels. Specificity should be high The kits should be Preferably CE- marked and IVD approved Evaluated and approved by NIB |
| 462 | 4.034 | Complement factor H (CFH) & related protein ELISA KIT | 1. Should detect, quantify the activity of CFH2. Preferably Ultra-sensitive assay 3. Should be compatible with automated as well as manual ELISA technique4. Should meet WHO/ NIB panels.5. Specificity should be high6. The kits should be Preferably CE- marked and IVD approved7. Evaluated and approved by NIB |

| 463 | 4.035 | PNH CARDS | 1. Should provide gel card centrifuge & incubator free of cost along with card. |
|-----|-------|--|---|
| 464 | 4.036 | HEPARIN PF4 CARDS | 1. Should provide gel card centrifuge & incubator free of cost along with card. |
| 465 | 4.037 | External Positive Controls for ELISA | Separate for HIV1/2, HBsAg, HCV Should be NIB Validated |
| 466 | 4.038 | Liquid stable External QC for TTI viral markers (Common) | Should include HBsAg and antibodies to HIV-1, HCV, HBc |
| 467 | 4.039 | Anti D quantification ELISA Kit | Should detect, quantify the activity of Anti D Preferably Ultra-sensitive assay Should be compatible with automated as well as manual ELISA technique Should meet WHO/ NIB panels. Specificity should be high The kits should be Preferably CE- marked and IVD approved Evaluated and approved by NIB |
| 468 | 4.040 | Reagent Red cells for antibody screen (three or two cell panel) | Should be ready for use 0.8% suspension for gel method Two to three pure reagent cells (not blend), which should include one R1R1 and one R2R2 cells Should be able to screen for antibodies against all clinically significant antigens endemic in Asia (including Mia). Should have shelf life of minimum 3 months (at least 45 days from date of delivery at AIIMS Jodhpur Blood Bank). Should be NIB and European IVD EC approved |
| 469 | 4.041 | Reagent Red cell panels (eleven cell panel) for antibody identifiction | Should be ready for use 0.8% suspension for gel method Panel 11 or more completely phenotyped red cells Should include all clinically significant antigens endemic in India Should include homozygous Jka&Jkb cells. Should include homozygous Jka&Jkb cells. (Fya&Fyb) Should have shelf life of minimum 3 months (at least 35 days from date of supply). Should be NIB and European IVD EC approved. |
| 470 | 4.042 | Newborn Blood Grouping Gel Cards | 1. For determination of ABO and Rho (D) status and direct Coombs test of neonates2. A-B-AB-D-Ctrl-AHG / One profile per card3. Six microtubes prefilled with gel in suitable buffer containing specific monoclonal antibodies Anti-A, Anti-B, Anti AB, Anti-D (VI-) and + monoclonal C3d) and neutral gel (negative control) in appropriate positions4. Stability: 4-25°C, 12 months5. Should provide gel card centrifuge & incubator free of cost along with card. |

AIIMS - Jodhpur 46 | Page

| 471 | 4.043 | Blood Donor Blood Grouping Cards | Forward & Reverse grouping Should provide gel card centrifuge & incubator free of cost along with card. |
|-----|-------|---|---|
| 472 | 4.044 | Red cell preserving solution | For preparation of cell panels in situ for serological applications |
| 473 | 4.045 | IgG Gel cards | 1. Should provide gel card centrifuge & incubator free of cost along with card. |
| 474 | 4.046 | 0.01 M Dithiothreitol (DTT) | >99.4% Purity (Preferably as solution) |
| 475 | 4.047 | 0.1 M glycine-HCl buffer (pH 1.5) | |
| 476 | 4.048 | 0.2 M Dithiothreitol (DTT) | |
| 477 | 4.049 | 1 N NaOH with PH 5.1 | |
| 478 | 4.050 | 1% Cystein Activated Papain | |
| 479 | 4.051 | 6% Bovine Serum Albumin | |
| 480 | 4.052 | 1.0 M TRIS (Tris(hydroxymethyl)aminomethane) - NaCl | |
| 481 | 4.053 | 10% Disodium ethylenediaminetetraacetic acid | |
| 482 | 4.054 | 2 Mercaptoethanol | |
| 483 | 4.055 | Aminoethyl isothiouronium bromide (AET) | |
| 484 | 4.056 | Bromelin Solution | |
| 485 | 4.057 | Chloroquine diphosphate Powder Form | |
| 486 | 4.058 | Chloroquine diphosphate Solution Form | |
| 487 | 4.059 | >99.9% Sterile DMSO 05% | |
| 488 | 4.060 | >99.9% Sterile DMSO 10% | |
| 489 | 4.061 | Dry ficin powder 1% | |
| 490 | 4.062 | Dry ficin Solution 1% | |
| 491 | 4.063 | Hypotonic Saline (0.3% v/v NaCL) | |
| 492 | 4.064 | L- Cysteine Hydrochloride | |
| 493 | 4.065 | L-cysteine hydrochloride (0.5 M) | |
| 494 | 4.066 | Papain | Preferably Liquid stable papain enzyme for serological applications |
| 495 | 4.067 | Papain | Lypophilysed Form |
| 496 | 4.068 | Phosphate Buffer Solution (PBS) | PH 7.3 |
| 497 | 4.069 | Phosphate-buffered saline (PBS) | pH 8.0 |
| 498 | 4.070 | Polyethelene Glycol (PEG) 3350 | |
| 499 | 4.071 | Polyethelene Glycol (PEG) 6000 | |
| 500 | 4.072 | RBC lysis Buffer 10X (flowcytometry grade) | |
| 501 | 4.073 | Sodium Citrate 3.8% | |
| 502 | 4.074 | Sodium Chloride (NaCl) Salt (reagent grade) | |

| 503 | 4.075 | ZZAP Reagent | Immunohematoloy IVD reagent grade combination of DTT & papain |
|-----|-------|---|---|
| 504 | 4.076 | ELISA Treponemal Test | |
| 505 | 4.077 | HBsAg Ultrasensitive Rapid | Sensntivity <2IU/ml |
| 506 | 4.078 | HBV Core Total (IgM+IgG) ELISA 96 well plates | |
| 507 | 4.079 | ANTI C (BIG) | |
| 508 | 4.080 | ANTI C (BIG) | |
| 509 | 4.081 | ANTI C (BIG) | |
| 510 | 4.082 | ANTI C (BIG) | |
| 511 | 4.083 | ANTI c (LITTLE) | |
| 512 | 4.084 | ANTI c (LITTLE) | |
| 513 | 4.085 | ANTI c (LITTLE) | |
| 514 | 4.086 | ANTI c (LITTLE) | |
| 515 | 4.087 | ANTI E (BIG) | |
| 516 | 4.088 | ANTI E (BIG) | |
| 517 | 4.089 | ANTI E (BIG) | |
| 518 | 4.090 | ANTI E (BIG) | |
| 519 | 4.091 | ANTI e (LITTLE) | |
| 520 | 4.092 | ANTI e (LITTLE) | |
| 521 | 4.093 | ANTI e (LITTLE) | |
| 522 | 4.094 | ANTI e (LITTLE) | |
| 523 | 4.095 | ANTI FYA | |
| 524 | 4.096 | ANTI FYA | |
| 525 | 4.097 | ANTI FYA | |
| 526 | 4.098 | ANTI FYA | |
| 527 | 4.099 | ANTI FYB | |
| 528 | 4.100 | ANTI FYB | |
| 529 | 4.101 | ANTI FYB | |
| 530 | 4.102 | ANTI FYB | |
| 531 | 4.103 | ANTI JK a | |
| 532 | 4.104 | ANTI JK a | |
| 533 | 4.105 | ANTI JK a | |
| 534 | 4.106 | ANTI JK a | |
| 535 | 4.107 | ANTI JK b | |
| 536 | 4.108 | ANTI JK b | |
| 537 | 4.109 | ANTI JK b | |
| 538 | 4.110 | ANTI JK b | |
| 539 | 4.111 | ANTI k (LITTLE) | |
| 540 | 4.112 | ANTI k (LITTLE) | |
| 541 | 4.113 | ANTI k (LITTLE) | |
| 542 | 4.114 | ANTI k (LITTLE) | |
| 543 | 4.115 | ANTI K (BIG) | |
| 544 | 4.116 | ANTI K (BIG) | |
| 545 | 4.117 | ANTI K (BIG) | |

| 546 | 4.118 | ANTIK (DIC) | |
|-----|-------|--|---|
| | | ANTI K (BIG) | |
| 547 | 4.119 | ANTI LE a | |
| 548 | 4.120 | ANTI LE a | |
| 549 | 4.121 | ANTI LE a | |
| 550 | 4.122 | ANTI LE a | |
| 551 | 4.123 | ANTI LE b | |
| 552 | 4.124 | ANTI LE b | |
| 553 | 4.125 | ANTI LE b | |
| 554 | 4.126 | ANTI LE b | |
| 555 | 4.127 | ANTI LU a | |
| 556 | 4.128 | ANTI LU a | |
| 557 | 4.129 | ANTI LU a | |
| 558 | 4.130 | ANTI LU a | |
| 559 | 4.131 | ANTI LU b | |
| 560 | 4.132 | ANTI LU b | |
| 561 | 4.133 | ANTI LU b | |
| 562 | 4.134 | ANTI LU b | |
| 563 | 4.135 | ANTI M | |
| 564 | 4.136 | ANTI M | |
| 565 | 4.137 | ANTI M | |
| 566 | 4.138 | ANTI M | |
| 567 | 4.139 | ANTI N | |
| 568 | 4.140 | ANTI N | |
| 569 | 4.141 | ANTI N | |
| 570 | 4.142 | ANTI N | |
| 571 | 4.143 | ANTI P1 | |
| 572 | 4.144 | ANTI P1 | |
| 573 | 4.145 | ANTI P1 | |
| 574 | 4.146 | ANTI P1 | |
| 575 | 4.147 | ANTI S (BIG) | |
| 576 | 4.148 | ANTI S (BIG) | |
| 577 | 4.149 | ANTI S (BIG) | |
| 578 | 4.150 | ANTI S (BIG) | |
| 579 | 4.151 | ANTI s (LITTLE) | |
| 580 | 4.152 | ANTI s (LITTLE) | |
| 581 | 4.153 | ANTI s (LITTLE) | |
| 582 | 4.154 | ANTI s (LITTLE) | |
| 583 | 4.155 | McCoy's 5% medium/solution pH 7.2, 500 ml | With L-glutamine, without sodium bicarbonate |
| 584 | 4.156 | HEPES BUFFER, 20 ML | 1 M, pH 7.0-7.6, sterile- filtered, |
| 585 | 4.157 | EOSIN Y, high purity, 100 g | ,,, |
| 586 | 4.158 | Fetal bovine serum, 500ml | Sterile filtered |
| 587 | 4.159 | Lymphocyte separation medium/Lymphoprep 500ml, 1.077 g/ml density, 500ml | sodium diatrizoate (9.1% w/v) and polysaccharide (5.7% w/v) |

| 588 | 4.160 | Formaldehyde solution 500ml | molecular biology grade, 36.5-38% in H20 |
|-----|-------|--|---|
| 589 | 4.161 | PHOSPHATE BUFFERED SALINE (10X) ph 7.5, 500ml | molecular biology grade, ph 7.4 |
| 590 | 4.162 | TRIS base, 500g | MB grade |
| 591 | 4.163 | TRIS EDTA buffer 500ml | MB grade, pH 7.0 |
| 592 | 4.164 | Ammonium chloride, 1 kg | Analytical grade |
| 593 | 4.165 | TRYPAN BLUE, 25 g | High purity/analytical grade |
| 594 | 4.166 | PH BUFFER (7.0) TABLETS, pack of 100 | |
| 595 | 4.167 | DTT (Dithiothreitol), 25g | molecular biology grade, ≥98% (HPLC) |
| 596 | 4.168 | Terasaki glass coverslip for 72 well tray, 100/pack | Dimension: 50 x 75 mm; thickness: 0.19-0.25 mm, clear polystyrene |
| 597 | 4.169 | Terasaki plates 72 well, 100 plates/pack | flat clear wells |
| 598 | 4.170 | CLASS I RABBIT COMPLEMENT- LYOPHILIZED 1ml | |
| 599 | 4.171 | Mineral oil, heavy, 1 L | refractive index- n20/D 1.467 (lit.); density- 0.862 g/mL at 25 °C |
| 600 | 4.172 | THROMBIN, lyophilised, 1g | Human origin |
| 601 | 4.173 | FIXED NEEDLE SOFT DROP SYRINGE- 50UL, (22s/51mm/2) | |
| 602 | 4.174 | FIXED NEEDLE SOFT DROP SYRINGE - 250UL, (22s/51mm/2) | |
| 603 | 4.175 | REPEATING DISPENSER FOR MICROSYRINGE | |
| 604 | 4.176 | ANTILYMPHOCYTE GLOBULIN (IgG) - POSITIVE CONTROL, 1mL | |
| 605 | 4.177 | COMPLEMENT CUP RACK | Stainless steel, holding capacity-6 |
| 606 | 4.178 | COMPLEMENT CUPS (100 UNITS/PACK) | Autoclavable, 10ml capacity, non-cytotoxic, non-wettable, polypropylene |
| 607 | 4.179 | COMPLEMENT COOLING SYSTEM | reusable Lucite cooling black with refreezable coolant. |
| 608 | 4.180 | 5% Human albumin, lyophilised, 1g | High purity |
| 609 | 4.181 | ACD vials 8.5ml or 9ml, pack of 100 | Medical device license & brochure should mention that it is sterile & suitable for making injectibles. Method for sterilization must be mentioned. |
| 610 | 4.182 | Rubber teats for pipettes, pack of 100 | |
| 611 | 4.183 | Class II complement lyophilized, 1ml | |
| 612 | 4.184 | Clot activator tubes, pack of 100 | |
| 613 | 4.185 | High Frequency Generator (Zapper) | With spring electrode tip |
| 614 | 4.186 | Tissue rolls (Lint free), pack of 180 | |
| 615 | 4.187 | Absolute Lymphocyte enrichment cocktail- Total Lymphocytes | |
| 616 | 4.188 | Human T-Cell enrichment cocktail- T Lymphocytes | |

AIIMS - Jodhpur 50 | Page

| 617 | 4.189 | Human B-Cell enrichment cocktail- B Lymphocytes | |
|-----|-------|---|---|
| 618 | 4.190 | Goat Anti-Human Kappa light chain immunoglobulin (AHG), 1ml | |
| 619 | 4.191 | Anti-T Lymphocyte (IgG) globulin, 1ml | |
| 620 | 4.192 | Anti-B Lymphocyte (IgG) globulin, 1ml | |
| 621 | 4.193 | Aluminum Canister (Cassettes) | Cassettes capable of reuse and can accommodate universal Cryo bags |
| 622 | 4.194 | Cryocassette Rack | For organing Cryocassettes parallelly stacks |
| 623 | 4.195 | DMSO GMP Grade | Sterile, Pyrogen fee, endotoxin free 100% DMSO Solution Vol-10ml or 70ml vials Compatible to Hematopoietic Stem cell cryopreservation |
| 624 | 4.196 | Sampling Coupler | For sampling and transfer of solutions and cells through ports of blood bags |
| 625 | 4.197 | Stem cell Identification and Enumeration Kit | For quantification of harvested stem cells by flowcytometry |
| 626 | 4.198 | Stem cell contol | For quality control |
| 627 | 4.199 | Ficoll-paque (Cell culture garade) | Specific gravity 1.077 |
| 628 | 4.200 | Trypan Blue | 0.40% |
| 629 | 4.201 | Dulbecco's PBS | Cell Culture Grade |
| 630 | 4.202 | Neubauer Hematocytometer | With Rhodium coated metallized counting surface |
| 631 | 4.203 | Nageotte Chamber | For QC of leukoreduction |
| 632 | 4.204 | RPMI-1640 cell culture medium | Stength-1X |
| 633 | 4.205 | DMEM (Dulbeccos modified Eagles Medium) | cell Culture grade 1X |
| 634 | 4.206 | Sealable sterile overwrap/pouch | |
| 635 | 4.207 | Albumin 20% | |
| 636 | 4.208 | HES 6% | |
| 637 | 4.209 | Spikers | |
| 638 | 4.210 | Flow Cytometry Sheath Fluid | |
| 639 | 4.211 | Stem Cell Enumeration Control | |
| 640 | 4.212 | Flowcytometry | |
| 641 | 4.213 | Flocytometer cleaning solution | |
| 642 | 4.214 | Flowcytometry Sample Loading Tube | |
| 643 | 4.215 | Dry ice | Ву Кд |
| 644 | 4.216 | Liquid Nitrogen | for tank refill |
| 645 | 4.217 | Cryovial | For Liquid Nitrogen Storage of samples |
| 646 | 4.218 | Cryobox | For Liquid Nitrogen Storage of samples |
| 647 | 4.219 | Cryogloves | For Liquid Nitrogen handling safety |
| 648 | 4.220 | Cryogoggles | For Liquid Nitrogen handling safety |
| 649 | 4.221 | Cryolabels | For Liquid Nitrogen Storage of samples |
| 650 | 4.222 | Plasma Racks | For organizing FFP Units |